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ABSTRACT 
The main purpose of this study was to investigate the possible mechanism(s) ofL­
carnitine-mediated modulation of AFB1-DNA adducts formation. The first part of the 
study investigated the effect of increased doses of carnitine on AFB 1 binding to 
macromolecules, AFB1 uptake, activity of glutathione S-transferase (GST), and total 
glutathione concentrations in freshly isolated hepatocytes. Carnitine dose was significantly 
correlated with the formation of AFB1-DNA adduct ( r = -0.68;p = 0.0002 ), AFBi­
protein adduct (r = 0.58;p = 0.017), but not AFB1-RNA adduct (r = 0.14;p = 0.604). 
There was no effect of carnitine on the uptake of AFB1 by the hepatocytes or on the 
activity of GST. Carnitine protected AFB1-induced reduction of total glutathione 
concentration in the hepatocytes, which may contribute to the overall protective effect of 
carnitine. The second part of the study investigated the effect of carnitine on the binding 
of microsomal-activated AFB1 to exogenous DNA and protein. Carnitine significantly 
decreased the binding of activated AFB1 to DNA. It is postulated that carnitine reduced 
this binding by inhibiting the AFB1-epoxide formation and/or binding of AFB 1-epoxide to 
DNA. This effect of carnitine was not very specific because acetylcarnitine and y­
aminobutyric acid were equally effective in reducing AFB1-DNA adduct formation; 
however, choline and glycine had no effect. Carnitine enhanced the binding of AFB 1 as 
well as microsomal-activated AFB1 to rat plasma proteins and bovine serum albumin. This 
mode of carnitine actions is proposed to be another mechanism of carnitine-mediated 
reduction of AFB1-DNA adduct formation. 
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CHAPTER 1 
Introduction 
We have reported earlier that camitine supplementation reduced aflatoxin B1 
(AFB1)-DNA adducts formation in rat liver (Sachan & Yatim 1992). Since AFB1-DNA 
binding is an important step for the carcinogenic effect of AFBi, the attenuation of the 
binding by camitine may decrease AFB1-induced carcinogenesis. However, the 
mechanism by which camitine modulates AFB1-DNA binding is still unknown. Therefore, 
the main focus of this dissertation research is to explore the mechanism( s) for camitine­
mediated decrease in AFB1-DNA adducts formation. 
I 
The in vitro experiments will be conducted employing freshly isolated liver cells 
(hepatocytes ), microsomes, and other biomolecules instead of intact animals. Advantages 
of conducting an in vitro experiment are that the experimental conditions can be easily 
controlled and, more importantly, that the use of laboratory animals can be minimized. 
Furthermore, since the activation of AFB1 is in the rnicrosome and the GSH conjugation is 
in the cytosol, experimentation using hepatocytes offers special advantages, such as the 
ability to monitor both activation and detoxification pathways of AFB1 could be monitored 
in the same preparation (Metcalfe and Neal 1983). Freshly isolated hepatocytes closely 
resembled the in vivo cells and their capacity for AFB1 biotransformation and thus allows 
direct monitoring of intracellular DNA adduct production (Bailey et al. 1982). The 
concern, however, was whether the carnitine effects found in the intact animals could be 
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reproduced in this in vitro system. Therefore, the first objective was to study the effect of 
carnitine on the AFB1-macromolecule adducts formation in the isolated hepatocytes. The 
results of these studies indicated that carnitine incubated in freshly isolated hepatocytes 
reduced AFB1-DNA binding as we had found in intact animals (Sachan & Yatim 1992). 
There are several possible mechanisms for camitine inhibition of the AFB1-DNA 
formation. Since carnitine has a positively charged�, an electrophilic center, AFB1-
epoxide may bind to camitine as the epoxide binds to DNA at the N7 position of guanine 
of DNA. As a result, the DNA may be spared from the electrophilic attack of AFB1-
epoxide. 
Carnitine may also influence the activation and/or detoxification processes of 
AFB1 • AFB 1 is first metabolized (Phase I metabolism) by the cytochrome P-450 enzyme 
system found in the microsome. This metabolism will produce a variety of metabolites 
such as AFB1-epoxide and hydroxylated metabolites (AFMi, AFP i, AFQi, and 
aflatoxicol). AFB1-epoxide is a very reactive and unstable metabolite of AFB1 that will 
bind to cellular DNA, RNA, and protein. The effect of camitine on microsomal AFB 1 
activation and on the binding of activated AFB1 (AFB1-epoxide) to exogenous DNA will 
be investigated. 
Carnitine may affect the Phase II biotransformation enzymes that are involved in 
detoxification of many xenobiotics and reactive molecules. Glutathione-S-transferase 
(GST) is the main enzyme that catalyzes the conjugation of AFB1-epoxide to glutathione, 
resulting in detoxicification of AFB1-epoxide. Therefore, the influence of carnitine on 
GST activity and total glutathione content in the hepatocyte will be studied. 
3 
We have reported that rats supplemented with camitine had a higher plasma 
concentration of AFB1 than the unsupplemented animals (Sachan and Yatim 1992). 
Therefore, the effects of camitine on AFB1-protein binding will also be studied. 
Also, AFB1 toxicity and carcinogenicity to cells will not have occurred if AFB1 
cannot permeate the plasma and nuclear membranes. Therefore, the role of carnitine in 
the uptake of AFB1 by the hepatocytes will be investigated. 
It is important to know the specificity of carnitine effect since there are a number 
of carnitine analogs ( acylcarnitine) and carnitine-like substances ( choline, gamma amino 
butyric acid). The carnitine-like substances may also affect AFB 1-DNA adducts 
formation and biotransformation of AFB1 • 
In summary, the questions that this research will address are: 
1. Can the modulation of AFB1-DNA adducts formation by camitine in vivo be 
duplicated in vitro? 
2. What is the effect of carnitine on AFB1-calfthymus DNA binding mediated 
by microsome? 
3. What is the effect of carnitine on GST activity and total glutathione 
concentration? 
4. Does carnitine have an effect on cellular uptake of AFB1? 
5. Is the inhibitory effect of AFB i-DNA binding specific for carnitine? 
4 
CHAPTER2 
Review of Literature 
Aflatoxins 
History 
Aflatoxins are a group of mycotoxins produced by the molds Aspergillus flavus 
and A. parasiticus. They are commonly found to contaminate food and feeds, such as 
milk, corn, peanuts, cottonseed, rice, and barley, grain-fermented beverages and edible 
animal tissues (Park & Pohland 1986). The current technology and knowledge can neither 
totally inhibit atlatoxins synthesis by the molds nor completely eliminate them once they 
are produced. As a result, the significance of aflatoxins contamination has long been 
recognized, and limits in agricultural commodities have been set since 1965. 
Aflatoxins were first discovered in 1960 when a series of outbreaks in poultry and 
fish occurred in different parts of the world. One of the worst outbreaks was the "Turkey­
X" disease that caused the deaths of many turkies, ducklings, and chicks in Britain (Blount 
1961 ). Consumption of atlatoxin-contaminated Brazilian groundnut meal was implicated 
in the disease. At the same time, feeding of contaminated corn, peas and cottonseed to 
farm animals and fish were reported to cause outbreaks analogous to the "Turkey-X" 
disease elsewhere (Palmgren & Ceigler 1983 ). 
Experiments conducted on the contaminated Brazilian peanut meal resulted in the 
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isolation of A. flavus, and when the fungus was inoculated into untainted peanut meal, the 
fungus produced toxins similar to those found in the contaminated meal (Sargeant 1961 ). 
The isolated toxins were named II atlatoxin. 11 
Structure and Toxicity 
Aflatoxin B1 (AFB1), B2 (AFBJ, G1 (AFG1), and G2 (AFGJ are the four main 
naturally occurring atlatoxins. The letters B and G refer to the atlatoxins' color under UV 
light (B for Blue; G for Green), and the subscripts 1 and 2 refer to their relative positions 
on a developed thin-layer chromatography plate. The structure of atlatoxins consists of a 
coumarin nucleus attached to a bifuran and either pentanone (AFB1 and AFB2) or a six­
membered lactone (AFG1 and AFG2) (Figure 2.1). AFB1 and AFG1 are more toxic to rats 
and ducklings as compared to AFB2 and AFG2 (Wogan et al. 1971). As for 
carcinogenicity, AFB1 is more carcinogenic than AFGi, while AFG1 is more carcinogenic 
than AFB2 (Shoenhard et al. 1981 ). 
The metabolites of atlatoxins produced in microbial or animal system include 
AFMi, AFM2, AFGMi, AFB:w AFG:w AFP i, AFQi, parasiticol and atlatoxicol. Although 
AFM1 is less carcinogenic than AFBi, their toxicities are about similar. AFG2a (also 
identified as AFB1 hemiacetal, atlatoxin W and hydroxydihydroatlatoxin) is relatively non­
toxic (Palmgren & Ceigler 1983 ). Aflatoxicol is the degradation product of AFB1 and is 
very toxic and carcinogenic to trout (Shoenhard et al. 1981 ). This is because atlatoxicol 
can be converted back to AFB1 by reductase and dehydrogenase enzymes (Loveland et al. 
1987). However, Gallagher & Eaton (1995) reported that the high rate of AFB1 
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biotransformation to aflatoxicol is one reason for Channel catfish being resistant to AFB1 
hepatocarcinogenesis. AFP1 is about 15 times less toxic than AFB 1 (Buehl et al. 1973). 
AFB 1 Toxicity and Carcinogenicity 
AFB1 is the most abundant and toxic form of all naturally occurring aflatoxins. It 
is hepatotoxic (O'Brien et al. 1983), hepatocarcinogenic (Adamson et al. 1976), and 
teratogenic (Bassir & Adekunle 1970) to various animal species. Rainbow trout (first) 
and rat (second) are the two animals most susceptible to the carcinogenic effects of AFB1 
as compared to other experimental animals (reviewed by Hendricks 1994). The Channel 
catfish is resistant to AFB1 toxicity and hepatocarcinogenicity mainly because AFB1 is not 
rapidly oxidized to form AFB1-epoxide but instead is rapidly metabolized to aflatoxicol 
(Gallager & Eaton 1995). AFB1 represents 75% of all aflatoxins found in contaminated 
food and feeds. The main target organs for AFB1 toxic and carcinogenic effects are the 
liver and kidney. 
Severe morbidity and deaths attributed to acute toxicity of AFB1 have been well 
documented in laboratory (O'Brien et al. 1983) and farm animals (Palmgren & Ceigler 
1983), and humans (Krishnamachari et al. 1975). The AFBi-DNA adducts formation has 
a strong correlation to animal and human cancer cases (Thabrew & Bababumi 1980; 
Wogan et al. 1971; Alpert et al. 1971; Groopman et al. 1988). The "Vutually Safe Dose" 
of AFB1 is estimated at 0.016 ng/kglday (reviewed by Eaton & Gallagher 1994). 
Hepatocellular carcinoma (HCC) is a major health problem in China where each 
year approximately 110,000 patients are diagnosed with it. The HCC cases in China 
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account for almost 45% of HCC incidences in the world (Parkin et al. 1984). The 
mortality rate for HCC is more than 95%. Excluding other risk factors, the consumption 
of AFB1-contaminated food such as corn, soya-based products, and peanut oil was 
correlated (r = 0.55) to the HCC fatality rates in people living in ten Chinese villages that 
were studied. See Yu (1995) for a current review ofHCC in China. 
AFB 1 Absorption 
9 
The absorption of AFB1 is quite efficient and fast as it has a low molecular weight 
and is lipophilic (Hsieh & Wong 1994). AFB1 is absorbed in the small intestine, and the 
duodenum is the most efficient site (Kumagai 1989). Since the absorption is roughly 
proportional to AFB1 concentration, this may indicate a passive absorption of AFB1 • Once 
absorbed, AFB1 goes into the mesenteric venous blood, into the hepatic portal vein, and 
finally into the liver. In an experiment involving ligated small intestines, the absorbed 
AFB 1 found in the mesenteric venous blood was in the form of free AFB i, protein bound, 
and water-soluble metabolites (Hsieh & Wong 1994). At 65 min post-AFB1 treatment, 
45% of the AFB1 dose was found in the ligated intestines, and 55% was found in the 
whole blood. About 32% of the dose present in the small intestines was bound to protein, 
and the rest was as free AFB i, and water-soluble and organic-soluble metabolites (Figure 
2.2). 
AFB 1 Metabolism 
Similar to other xenobiotics (foreign substances), AFB1 undergoes phase I and 
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FIGURE 2.2 The percentage of[14C]AFB 1 dose absorbed from ligated duodenum of 
rats. 
Source: Hseih, D.P.H. & Wong, J.J. ( 1 99 4) Pharmacokinetics and excretion of 
aflatoxins. In : The Toxicology of Aflatoxins: Human Health, Veterinary and 
Agricultural Significance (Eaton, D. L. & Groopman, J. D., eds.), pp. 73-88 .  
Academic Press, New Y orlc, NY. 
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phase II biotransformations or metabolisms (reviewed by Eaton et al. 1994). The 
metabolism in vivo or in vitro may results in several different derivatives of the mycotoxin. 
The liver and kidney are the two main organs where AFB1 is metabolized. In vitro, AFB1 
undergoes at least five different types of metabolic reactions with liver enzyme 
preparations, which are hydroxylation, hydration, reduction, 0-demethylation, and 
epoxidation (Figure 2.3). During the phase I biotransformation, depending on the 
pathways, AFB1 can either be activated or transformed into less toxic compounds. Phase 
II pathways involve different transferase enzymes that catalyze the detoxification 
( conjugation) reactions of the Phase I metabolites. Species differences, health status, 
nutritional manipulations, drugs, and chemicals treatments affect the biotransformations, 
and thus, the potency of AFB1 . 
Phase I metabolism 
AFB1 has to be activated for it to possess toxic and carcinogenic effects. The 
phase I biotransformation pathways of AFB1 with microsomal cytocrome P450 (CYP) 
system produced metabolites, such as the reactive AFB1-8,9-epoxide, the more polar 
(hydroxylated) AFM1 and AFQi, the 0-demethylation AFP i, and the reduced aflatoxicol. 
The biotransformation rates of AFB1 to AFM1, AFP 1, and AFQ1 in human liver slices were 
comparable to those found in rat liver slices. Nevertheless, the production of AFB1-
epoxide and bindings of AFB1 to cellular DNA, RNA, and protein were much lower in 
human liver slices than in rat liver samples (Heinonen et al. 1996). The AFB1-8,9-epoxide 
may covalently bind to cellular DNA and other macromolecules, form AFB1-glutathione 
Aflato1,n e,.. 
FIGURE 2.3 Metabolism of AFB1 . 
Source: Eaton et al. ( 1 994) Biotransfonnation of aflatoxins. In: The Toxicology of 
Aflatoxins: Human Health, Veterinary and Agricultural Significance (Eaton, D. L. & 
Groopman, J .D. , eds. ). pp. 45-72. Academic Press, New York, NY. 
1 2  
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conjugate, hydrolyze to form AFB1-8, 9- dihydrodiol, and/or reduced to a hemiacetal 
form. In rats, CYP1A2, CYP2C 1 1, and CYP3A4 isoforms or genes have been found to 
activate AFB1 • Whereas in human, CYP1A2, 2A6, 2B7, 3A3 and 3A4 are involved in 
AFB1-epoxide production (Forrester et al 1990; Eaton & Gallagher 1994; Eaton et al. 
1994). 
The formation of AFBi-DNA adduct is highly correlated to the carcinogenic effect 
of AFB1 in both in vivo and in vitro studies (Dragan & Pitot 1994, ). The major AFB1-
DNA adduct formed with liver DNA is atlatoxin B1-N7-guanine (AFB1-N7-gua) 
(Essigmann et al. 1977). This adduct is unstable and subjected to decomposition. The 
major decomposed derivatives of AFB1-N7-gua in rat liver are the imadozole ring-opened 
AFB1 formamido-pyrimidine adducts, namely AFB1-N7-FAPY major and minor (Croy & 
Wogan 1981). AFB1-N7-FAPY adducts are more stable, and their accumulation in liver 
DNA is related to the subsequent reduction of AFBi-N7-gua adduct level. 
AFB1 can also be activated by other reactions not involving cytochrome P450 
system. Prostaglandin H synthase (Liu et al. 1990), lipoxygenase (Liu & Massey 1992), 
and UV light (Stark et al. 1990) have been shown to activate AFB1 • 
Phase n metabolism 
The phase I AFB1 metabolites may undergo phase II biotransformation involving 
the enzymes glutathione S-transferase (GST), �-glucuronidase, and/or sulfate transferase 
which produce conjugates of AFB1-glutathione, AFB1-glucuronide, and AFB1-sulfate, 
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respectively. The major conjugate of AFB1-epoxide identified is the AFB1-glutathione 
conjugate (Monroe & Eaton 1987; O'Brien et al. 1983). This conjugation is the principal 
detoxification pathway of activated AFB1 in many mammals (Figure 2.4). It has been 
accepted that cytosolic GST activity is inversely correlated to susceptibility of the several 
animal species to AFB1 carcinogenicity (Eaton & Gallager 1994, Neal 1987). 
The hydoxylated (AFM1 and AFQ1) and 0-demethylated (AFP1) metabolites of 
AFB1 can undergo glucuronidation and sulfation. Glucuronidation, catalyzed by liver 
microsomal UDP-glucuronyl transferase (UDPGT), has been reported for a variety of 
endogenous and foreign compounds (Burchell & Coughtrie 1989). In rat hepatocytes, 
AFP 1 is a better substrate for glucuronide conjugation than AFM1 and AFQ1 (Metcalfe & 
Neal 1983). AFP 1-glucuronide conjugate is the only significant glucuronide or sulfate 
conjugate other than the other two AFB1 metabolites (AFM1 and AFQ1) in rat liver cells ' 
(Ch'ih et al. 1983). These conjugations results in formations of water-soluble atlatoxin 
esters that are excreted in the urine or bile (Hseih & Wong 1982). Refer to Figure 2.5 for 
an overview of AFB 1 metabolism pathways that lead to its toxic and carcinogenic effects. 
AFB 1 Metabolism in the Small Intestine and Blood, and Binding to Proteins 
Although the major sites for AFB1 metabolism are in the liver and kidney, there are 
suggestions that some biotransformation may also occur in the small intestine. (Hartiala 
1977; Vainio & Hietanen 1979). The intestinal mucosa contains cytochrome P450 
enzymes and has been suggested to be the site for the metabolism of AFB1 . The intestinal 
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metabolism produces metabolites, such as AFB1-epoxide, AFB2a,and AFB1 dihydrodiol, 
that may bind covalently to proteins. 
It has also been suggested that there is some detoxification of AFB1 metabolites in 
the gut by the phase II detoxification enzymes (Hsieh & Wong 1994 ). This suggestion 
was made due to the absence of organic-extractable AFB1 metabolites in the blood. The 
authors concluded that since the liver has high capability to draw free AFB1 from the 
blood, AFB1 binding to serum albumin after absorption from the intestine could be one of 
the major detoxification processes of AFB1 . At low doses of AFBi, they found no free 
AFB1 in the blood. This is because the absorbed AFB1 readily binds to albumin. Albumin 
serves as the major transporter of AFB1 in the blood since very little AFB1 was bound to 
other blood proteins (Dirr & Scabort 1987). Because of the high levels of accumulation 
and occurrence, serum albumin adduct is currently used as a biomarker for AFB1 exposure 
in humans (Chang et al. 1994). 
The presence of AFB1-albumin adducts in serum (Sabbioni et al. 1987) indicates 
that AFB1 is metabolized either in the intestine or in blood compartments. Blood platelets 
contain cytochrome P450, prostaglandin synthase (Hodgston & Levi 1994) and 
lipoxygenase (Liu & Massey 1992), which are capable of activating AFB1 • Therefore, it 
may be that these enzymes catalyze the formation of AFB1-epoxide found in the blood, 
and that epoxide then binds to albumin. However, another study reported that a very high 
percentage of AFB1 bound to rat plasma albumin noncovalently (more than 95%) 
(Ewaskiewicz et al. 1991 ). This indicates that AFB1 does not have to be metabolized first 
for it to bind to albumin and that albumin serves as major transporter of AFB1 in the blood 
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to the liver. 
Hirano et al. (1994) studied the probable role ofbovine serum albumin (BSA) in 
inhibiting the toxicity and absorption of AFB1 in one-day-old chicks. The BSA was given 
intragastrically prior to AFB1 administration. BSA treated chicks showed less AFB1-
induced liver damages such as bile duct proliferation and necrosis than did the non-BSA 
treated animals. AFB1 concentrations in the liver and plasma were also lowered in the 
BSA treated animals 6-h post-AFB1 treatment, at which time the AFB1 level was at the 
maximum. These phenomena might be due to an increased binding of AFB1 to BSA in the 
intestine. Since macromolecules (which include AFBi-BSA adduct) cannot be absorbed 
from the small intestine of a one-day-old chick, it was postulated that the BSA adduct was 
rapidly excreted without absorption. 
AFB 1 and Diet Interactions 
There are many reports on the effects of various food or nutrients and xenobiotics 
on AFB1-macromolecule adducts formation. Obviously, the major objectives of these 
studies have been to determine if and how those nutrients or xenobiotics could affect 
adducts formation, especially DNA adduct (see Tables 2.1 and 2.2). 
Fat-soluble vitamins 
A number of vitamins and vitamin analogs have been tested on AFB1-
macromolecule adduct formation. Bhattacharya et al. (1984; 1987) reported 
comprehensive studies on the effects of various vitamins on in vitro adducts formation. 
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TABLE 2.1 
Influences of dietary nutrients on AFB1-DNA adducts formation. 
Compound* Test System Increase (T)/Decrease ( l) Reference 
Low Protein Rat liver T Mandell et al . ( 1 992) 
Low fat Rat liver T Nyathi et al . ( 1 993) (high carbohydrate) 
Fat (Saturated or Rat liver NSE* Marzuki & Norred unsaturated) ( 1984) 
Essential oils Rat liver microsome l Hashim et al . ( 1 994) 
Vitamin A Rat liver l Bhattacharya et al . ( 1 989) Rat liver NSE Chen et al . ( 1 982) Woodchuck hepatocyte l Yu et al . (1 994) 
�-carotene Woodchuck hepatocyte T Yu et al . (1 994) 
Vitamine E Woodchuck hepatocyte T Yu et al. (1 994) 
Riboflavin Rat liver l Webster et al . ( 1 996) 
Vitamin B6 Rat liver microsome NSE Bhattacharya et al . ( 1 984) 
Thiamin Rat liver microsome NSE Bhattacharya et al . ( 1984) 
Vitamin C Woodchuck hepatocyte l Yu et al . (1 994) 
Lipotropes ( deficient) Rat liver l Campbell et al . ( 1 978) 
Continued 
2 1  
TABLE 2.1 :  Continued 
Compound* Test System Increase (J)/Decrease ( l) Reference 
Camitine Rat liver l Sachan & Yatim 
( 1 992) 
Choline ( deficient) Rat liver - Single AFB 1 dose NSE Schrager et al . ( 1 990) - Multiple AFB 1 doses T Schrager et al . ( 1 990) 
Copper Rat liver microsome l Bhattacharya et al . 
(1 984) 
Selenium Rat liver l Chen et al . ( 1 982) (Excess or deficient) 
Selenium Chick liver NSE Chen et al. ( 1 982) 
Selenium Hamster ovary cells NSE Shi et al . ( 1995) 
Feed restriction Rat liver l Pegram et al . ( 1 989) Gao & Chou ( 1 992) Chen et al . ( 1 995) 
lndole-3-carbinol Trout liver ! Dash wood et al . 
( 1 989) Trout liver microsome l Takahasi et al ( 1995) 
R-goitrin Rat liver l Chang & Bj eldanes 
( 1987) 
Curcumin Rat liver microsome l Firozi et al . ( 1 996) 
*NSE, no significant effect 
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TABLE 2.2 
Influences of xenobiotics on AFB1-DNA adducts formation. 
Compound* Test System Increase (l)/Decrease (l) Reference 
BHA Rat liver microsome l Bhattacharya et al. ( 1 984) 
Rat liver l Chang & Bjeldanes ( 1987) 
Trout liver NSE** Goeger et al . ( 1988) 
Rat and mouse livers l Monroe & (Eaton 1987) 
BHT Rat liver microsome ! Bhattacharya et al . ( 1 984) 
Cortisol Rat liver T Chentanez et al. ( 1 988) 
Crocetin Fibroblast cell l Wang et al . ( 1 99 1  a) 
DDB Rat liver ! Liu et al . ( 1995) 
Ethoxyquin Rat liver ! Kensler et al . (1 986) 
Ethanol Rat liver ! Toskulkoa & Glinsukon 
( 1986) 
Geniposide Rat Liver l Wang et al . ( 199 1b) 
Rat liver microsome l Wang et al . ( 1 992) 
Phenobarbital Rat liver l Lotlikar et al . 1 989) 
*BHA, butylated hydroxyanisole; BHT, butylated hydroxytoluene; DDB; dimethyl-4,4' 
dimethoxy-5,6,5 '6'-dimethylenedioxy biphenyl-2,2' dicarboxylate. 
**NSE, no significant effect 
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Vitamin A supplemention in rats inhibited AFB1-DNA binding (Bhattacharya et al 
1989). The protective effects of retinoids such as retinol, retinal, retinoic acid, and retinal 
esters on AFB1 carcinogenicity were due to inhibition of AFB1-DNA adduct formation by 
affecting the CYP450 systems resulting in less epoxide being formed (Bhattacharya et al. 
1984). Retinal had the same inhibitory effect on the formation of AFB1-protein adducts 
(Bhattacharya et al. 1989). Vitamin A has been shown to induce the activity of 
glutathione S-transferase, thereby enhancing the detoxification of AFB1-epoxide 
(Bhattacharya et al. 1989). On the other hand, vitamin A deficiency decreased glutathione 
S-transferase activity. 
However, another study reported that a vitamin A supplement had no significant 
effect on AFB1-macromolecules binding in rats. On the contrary, a combined deficiency of 
vitamin E and selenium decreased AFB1 binding to DNA, RNA, and protein (Chen et al. 
1982). Vitamin E and menadione (a water-soluble synthetic vitamin K) have been found 
to prevent AFB1-induced mutagenesis in the Ames bacterial system (Raina & Gurto 1985). 
�-carotene and vitamin E increased DNA adduct formation in woodchuck hepatocytes 
(Yu et al. 1994). 
Water-soluble vitamins 
Riboflavin, riboflavin-5'-phosphate (FM.N), and flavin adenine dinucleotide (FAD) 
inhibited AFB1-DNA adduct formation in vitro. Riboflavin was reported as the most 
effective of the three vitamins (Bhattacharya et al. 1984). It has been recently suggested 
that the mechanism for the riboflavin effect is its ability to induce. the enzymes involved in 
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repairing damaged DNA (Webster et al. 1996). 
Vitamin C, vitamin B6 and thiamin had no significant effect on DNA adduct 
production (Bhattacharya et al. 1984). However, vitamin C, B6, and folic acid inhibited 
mutagenesis in bacterial systems (Bhattacharya et al. 1984; Bhattacharya et al. 1987). The 
inhibition by vitamin C was not as great as with the fat-soluble vitamins. 
In a study employing woodchuck hepatocytes to find the role of vitamins A, C, and 
E, and �-carotene on the initiation of AFB1-induced carcinogenesis, the workers found 
that vitamin A was more effective than vitamin C in inhibiting DNA adduct formation. In 
contrast, vitamin E and �-carotene enhanced the binding (Yu et al. 1994). Therefore, 
these results suggest that different antioxidant vitamins may effect AFB1-DNA binding 
differently. 
Amino acids 
There are conflicting reports on the effects of different amino acids on AFB1 
carcinogenesis. A diet marginally deficient in methionine (which was also deficient in 
choline and lacking in folacin) depressed DNA and RNA adducts formation in rat liver. 
Protein adduct formation was not affected by the diet. The inhibition of AFB1-nucleic acid 
adducts in the marginally lipotrope-deficient diet was due to the decrease in the activation 
of AFB1 and not due to an increase in glutathione levels (Campbell et al. 1978). A choline 
and methionine-deficient diet fed rats showed no significant AFB1 dose-response changes 
in serum biochemical parameters or liver pathology compared to the complete amino acid 
diet (Mehta et al. 1993). These two studies treated the rats with a single dose of AFB1 . 
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Schrager et al. ( 1 990) found that a single dose of AFB 1 did not affect the DNA 
adduct concentration in both choline-deficient and control animals. However, when 
multiple doses of AFB 1 were administered, the AFB 1-DNA adduct levels were 
significantly higher in the rats fed a choline-deficient diet than in the rats fed with a control 
diet. An earlier report also found that marginally deficient lipotrope diets induced AFB 1 
tumorigenesis in rats (Rogers & Newbeme 1 9 69). L-carnitine supplementation in rats has 
been found to decrease AFB.-DNA binding (Sachan & Yatim 1 99 2). 
Sulfur-containing amino-acids such as cysteine, N-acetylcysteine, cystine, 
methionine, and glutathione inhibited AFB 1 mutagenicity in microbial systems. Cysteine 
and N-acetylcysteine were more potent inhibitors than glutathione. The investigators 
suggested that the inhibition was due to amino acids affecting the synthesis of AFB 1-
epoxide (Shetty et al. 1 989). 
Protein 
Weanling rats fed a low protein diet (5% casein) had fewer AFB 1-induced 
preneoplastic foci in their livers than rats fed a high protein diet ( 200/o casein) (Youngman 
& Campbell 1 99 2). The enhanced development of the preneoplastic foci ( y-glutamyl 
transpeptidase-positive foci) by the high protein diet was reversed when the animals were 
put on a low protein diet. Thus, it was concluded that the low protein diet prevented 
lesions caused by AFB 1 • 
Mandell et al. ( 1 99 2) reported that AFB 1-induced hepatocarcinogenicity can occur 
in both low- and high-protein fed weanling animals. Moreover, the low protein diet ( 5% 
lactalbumin) also caused severe liver histopathological changes or sub-acute toxicity 
symptoms such as necrosis and bile duct proliferation due to AFB1 . Also, the protein­
deficient animals had a more rapid decrease in glutathione S-transferase activity than the 
protein-sufficient ( 200/o lactalbumin) animals . High protein fed animals did not show the 
sub-acute toxicity responses induced by AFB 1 . Therefore, the authors suggested that 
protein deficiency is more likely to enhance, rather than protect the liver against, AFB 1 
toxicity and carcinogenicity . 
Fat and essential oils 
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Di fferent types and amounts of fat may have di fferent effects on the carcinogenesis 
of AFB1 • High polyunsaturated oil ( com oil) increased the incidence of liver cancer in rats 
caused by AFB1 as compared to rats fed with saturated oil (beef fat). The cancer 
incidence was higher when the com oil was fed with or after the exposure to AFB1 than 
when the oil was fed before the AFB 1 dose. An increase in induction of AFB 1 activation 
by com oil was suggested for the high cancer incidence (Newbeme et al. 1 9 7 9). 
However, in a similar study, saturated ( coconut oil ) and unsaturated dietary ( com oil ) fats 
were found to have no significant effect on the adduct formation and the production of 
AFB1-epoxide in rat livers (Marzuki & Norred 1 9 8 4) .  
In another report, the metabolism and mutagenicity of AFB 1 were not significantly 
di fferent between mice fed with beef fat and olive oil diets (Brennan-Craddock et al. 
1 9 90). With respect to the levels of dietary fat, a low-fat (high carbohydrate) diet 
increased the AFB1-DNA binding more than a high fat diet (Nyathi et al . 1 9 9 3) . The 
protective effect of a high fat diet may be due to a decrease in the uptake of AFB1 into 
hepatocytes or a reduction of AFB1-epoxide production. 
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Hashim et al. (1994) investigated the capability of essential oils extracted from 
nutmeg, ginger, cardamom, celery, xanthoxylum, coriander, cumin, and black pepper to 
inhibit AFB1-DNA adducts formation mediated by liver microsomal enzymes. All the 
essential oils tested were suppressive to the adducts formation, and the inhibition was 
dose-dependent. The modulating effect of these oils was through their ability to inhibit the 
activation of AFB1 • 
The presence of long chain fatty acids at their physiological concentrations 
increased the strength of AFB1-albumin binding considerably (Dirr 1987). The binding 
affinity (ka) was increased by 3-fold when the pH was raised from 6 to 9. The presence of 
palmitic, stearic, and oleic acids ( the most abundant plasma fatty acids) at the 
concentration range of0.5  to 2.0 mol/mol albumin, further increased the albumin binding 
of AFB1 to greater than 4 times at pH 7.4 (Dirr 1987). 
Trace elements 
Copper inhibited AFBi-DNA binding in vitro (Bhattacharya et al. 1984). A 
deficiency and an excess of selenium decreased the adduct formation in rats. In chicks, 
however, excess of selenium did not change the concentration of adducts formed (Chen et 
al. 1982). Recently, selenium was demonstrated to have no effect on DNA adduct 
formation in ovary cells and did not effect AFB1 mutagenesis (Shi et al. 1995). 
Copper, manganese, zinc, and selenium were effective in preventing in vitro AFB1-
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induced mutagenesis. Copper was the most potent among the elements tested. To a 
lesser extent, iodine, molybdenum, cobalt, and iron were antimutagenic. The investigators 
suggested that the inhibition was due to interaction of trace elements with the microsomal 
enzymes (Francis et al. 1 988). 
Feed restriction 
The potentially protective effects of caloric restriction on cancer-causing 
compounds has promoted considerable interest and investigation. It has been reported 
that rats fed with 60% of the food consumed by ad libitum animals had lower AFB1 
microsomal activation, lower AFB1-adducts, faster plasma clearance, and increased 
urinary excretion of AFB1 than the ad libitum fed animals. The authors concluded that 
40% feed restriction may decrease AFB1 carcinogenicity (Pegram et al. 1 989). 
Similarly, about more than 50% reduction in AFB1-DNA binding was found when 
rats were fed 40% caloric restricted diet (Gao & Chou 1 992). The restriction also 
decreased the hepatic DNA double strand damage induced by AFB1 • Induction in 
glutathione S-transferase activity in feed restriction will enhance AFB1-epoxide 
conjugation to GSH and thus reduce AFB1-DNA adducts formation (Chen et al. 1 995). 
Cruciferous vegetables 
Cruciferous vegetables have been shown to enhance detoxification of xenobiotics 
by inducing xenobiotic-metabolizing enzymes in animals and humans (Salbe & Bjeldanes 
1989). High consumption of vegetables such as broccoli, cabbage, cauliflower, and 
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Brussels sprouts has been related to a reduced risk of bladder, colon, and rectum cancers 
(Grahams 1983). 
Brussels sprouts significantly decreased AFB1-DNA binding and increased the 
GST activity in rats. lndole-3-carbinol, a compound found in cruciferous vegetables, did 
not have much effect on the DNA binding and GST activity (Salbe & Bjeldanes 1989). 
The same investigators also found that the route of administration, intragastric or 
intraperitoneal, did not have a different effect on AFBi-DNA binding. Thus, they 
concluded that the small intestine did not play an important role in AFB 1 metabolism. 
However, in another study that utilized trout, 1000 and 2000 ppm of indole-3-carbinol 
were shown to strongly depress AFB1-DNA adducts formation (Dashwood et al. 1989). 
R-goitrin, another compound found in cruciferous vegetables, also exhibited 
anticarcinogenic properties such as inhibition of AFB1-DNA binding, induction ofGST 
activity, and enhancement ofbiliary excretion of AFB 1 in rats (Chang & Bjeldanes 1987). 
Plant flavonoids and phenolic compounds 
Five major derivatives of plant flavonoids, namely flavone, flavonol, isoflavone, 
and flavonol, have been tested on activation of AFB1 and AFB1-DNA adducts formation 
(Bhattacharya & Firozi 1988). Most of the flavonoid derivatives significantly inhibited 
adduct formation, and flavonols being the most potent. Flavonols also showed greater 
inhibition of AFB1 mutagenicity in bacterial system (Goeger et al. 1988). 
Phenolic compounds may have protective effects against AFB1-induced 
mutagenicity. Gallic acid, chlorogenic acid, caffeic acid, dopamine, p-hydroxybenzoic 
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acid, and salicyclic acid decreased mutation caused by AFB1 in bacterial system containing 
rat-liver microsomes. The inhibition occurred when the compounds and AFB1 were 
administered concurrently (San & Chan 1987). Using the S9 liver fraction that contains 
the metabolic enzymes, ellagic acid ( a compound found in strawberries, grapes, and 
walnuts) has been shown to be antimutagenic against AFB1 in bacterial assay (Loarca-Pina 
et al. 1996). The inhibition was greatest when the acid was incubated together with AFB1 . 
Curcumin, a phenolic compound extracted from tumeric, was recently reported to 
inhibit the production of AFB1-epoxide by affecting CYP enzyme function (Firozi et al. 
1996). The inhibition became higher as the curcumin concentration was increased in the 
incubation mixture. However, the suppression was reversed when the CYP level in the 
mixture was higher. 
AFB1 and Drugs!Xenobiotics Interactions 
Antioxidants 
Rats fed a butylated hydroxyanisole (BHA)-containing diet had lower AFB1-DNA 
binding, higher GST activity, and higher biliary excretion of AFB1 (Chang & Bjeldanes 
1987). Animals treated with butylated hydroxytoluene (BHT) before or together with 
AFB1 had lower cancer incidences than the animals administered AFB1 alone (Dragon and 
Pitot 1994). However, in trout, BHA did not effect liver tumor incidence, AFB1-DNA 
binding, or AFB 1-glutathione conjugation (Goeger et al. 1988). In in vitro system, both 
BHA and BHT inhibited AFB1-DNA binding (Bhattacharya et al. 1984). Another 
antioxidant, ethoxyquin, also suppressed AFB1 carcinogenesis by inducing the activity of 
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glutathione S-transferase activity (Kensler et al. 1986). 
Ethanol 
Ethanol is a known carcinogen or procarcinogen (Yirmaya & Taylor 1993). 
Ethanol is metabolized in the liver by alcohol dehydrogenase, microsomal ethanol­
metabolizing system (MEOS), and catalase (Odeleye & Watson, 1992). CYP2E l enzyme 
( also known as rat P450j) is the major :MEOS that is influenced by ethanol. The induction 
of CYP2E 1 by ethanol consumption was implicated in alcohol-induced liver diseases 
(Nanji et al. 1 994). CYP2El has also been reported to activate certain liver toxins and 
chemicals (lngelman-Sunberg et al. 1 988). 
Ethanol, when given to animals together with or prior to aflatoxin, increased the 
aflatoxin hepatotoxicity and DNA binding (Toskulkoa & Glinsukon 1 986; Toskulkoa et al. 
199 1 ;  Sahaphong et al. 1 992). The alcohol pretreatment increased the activation of AFB 1 
but not the GST activity. This explains the increased binding of AFB1 to DNA. On the 
other hand, when given after AFB1 administration, ethanol showed no influence on AFBi­
DNA binding (Messlbeck et al. 1984). 
Other Drugs/Xenobiotics 
The activities of CYP, GST, and UDPGT enzymes can be induced by several 
drugs or xenobiotics. Enzyme inducing drugs such as phenobarbital ( anti-seizure drug) 
and Aroclor 1254, given before or together with AFBi, reduced the number of neoplasms 
as compared to animals given AFB1 only (Dragan and Pitot 1994). Although phenobarbital 
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enhanced AFB1 activation, it also induced GST activity and thus increased AFB1-
glutathione conjugation. Therefore, the overall hepatic binding of AFB1 to DNA is 
reduced (Loury et al. 1 984; Lotlikar et al. 1989). Other inducers such as ethoxyquin 
(Kensler et al. 1986), and oltipraz (Primiano et al. 1995), have also been shown to inhibit 
AFB1-induced carcinogenesis by inducing GST activity. In a study employing human 
hepatocytes, oltipraz was also reported to lower the the production of AFB 1-epoxide by 
inhibiting the CYP1A2 and CYP3A4 activities (Longouet et al. 1995). 
A compound isolated from a Chinese herb, dimethyl-4,4'dirnethoxy-5,6,5',6'­
dirnethylenedioxy biphenyl-2,2'-dicarboxylate (DOB), is a drug used for its liver protective 
effects. Pretreatment of rats with DOB inhibited liver damage caused by AFB1 • DOB also 
induced the activity of glutathione S-transferase and therefore enhanced detoxification of 
AFB1-epoxide (Liu et al. 1995). Crocetin, a carotenoid isolated from the seeds of Cape 
jasmine, has been reported to elevate the cytosolic glutathione S-transferase activity and 
glutathione concentration in a fibroblast cell line treated with AFB1 (Wang et al. 1991a). 
Another Chinese herbal drug, geniposide, isolated from a fruit of a species of gardenia, 
can also inhibit AFB1-induced DNA binding. Induction of glutathione S-transferase and 
gamma glutamyl cysteine synthase (involved in glutathione synthesis) activities, and 
suppression of AFB1-induced unscheduled DNA synthesis were the suggested mechanisms 
of action of geniposide (Wang et al. 1991b; Wang et al. 1992). 
Cortisol pretreatment in rats markedly increases the acute hepatoxicity of AFB1 
(Chentanez et al. 1988). The toxicity effects, such as higher mortality rates, increased in 
liver triacylglycerol, and elevated AFB1 binding to DNA and protein, were dose-
dependent. These cortisol effects may by due to increased metabolism of AFB1 to its 
epoxide derivative. 
Carnitine 
History 
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Carnitine was discovered from muscle extracts by two Russian scientists in 1905 
(reviewed by Leibovitz 1984). It was named carnis, which is a Latin word for flesh or 
meat. In the l 940's, camitine was found to be essential for the mealworm by Fraenkel and 
was named Vitamin Bt. In the late l 9SO's and early 60's, it was discovered that camitine is 
involved in the transportation of fatty acids into the mitochondria for P-oxidation (Fritz 
1959). However, it was not until 1973 that camitine gained much attention and 
investigation, when the first camitine deficient patient was described (Engel & Angelini 
1973). 
Chemistry and Dietary Sources 
Carnitine is a quarternary amine and is very similar to choline and amino acids. 
However, unlike amino acids, carnitine does not involve in protein synthesis. Chemically, 
it is known as 3-hydroxy-4-N-trimethylamino butyric acid. It exists as D and L isomers, 
but only the L-isomer is biologically active. The D-isomer is not only inactive, it can also 
depress L-carnitine utilization (reviewed by Leibovitz 1987). Carnitine is present in the 
body as free camitine and as acylcamitine (fatty acyl-camitine ester). 
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Camitine can be produced in the body, and therefore it is not essential to humans 
and is not considered to be a vitamin. Muscle, liver, yeast, and milk are very good sources 
of dietary camitine. Most vegetables and grains such as cauliflower, cabbage, spinach, 
barley, and rice have very little or no camitine. The detailed reviews of carnitine history, 
biosynthesis, dietary sources and functions are available (Leibovitz 1984; Leibovitz 1987; 
Borum 1983). 
Structure of L-Carnitine 
Carnitine Biosynthesis 
The biosynthesis of carnitine starts from two essential amino acids, lysine and 
methionine, and involves five different enzymes in a five step pathway (Figure 2.6). 
Niacin, vitamin B6, vitamin C. and iron are also required for for the biosynthesis of 
carnitine in animals (Borum 1983). 
step 1 
( repeated 3 times) 
step 2 
step 3 
lysine 
r 
N-trimethyl­
lysine 
N-trimethyl-3-
hydroxy lysine 
4-N-trimethylamino 
butyraldehyde 
step 4 .-­
step 5 
4-N-trimethylamino butyric acid 
Camitine 
(3-hydroxy-4-N trimethylamino butyric acid) 
FIGURE 2. 6 Biosynthesis of carnitine. 
I 
SAM 
(SAM lysine 
methyltransferase) 
Vit. C, iron, oxygen, 
alpha-keto glutarate 
(N-trimethyllysine beta­
hydroxylase) 
B6 
(Aldolase) 
( dehydrogenase) 
Vit. C, iron, oxygen, 
alpha-keto glutarate 
( butyrobetatne 
hydroxylase) 
Source: Leibovitz (1984) Carnitine: How it functions in your body. In: 
Carnitine: The Vitamin Bt Phenome� pp 24-38. Dell Publishing Co. ,  Inc., 
New York. 
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In rats, the first 4 steps of the pathway occur in the liver, kidney, skeletal muscle, 
cardiac muscle, testis, and epididymis. However, the final step occurs only in the liver. In 
humans, the liver, kidney, brain, heart, and skeletal muscle can convert N-trimethyllysine 
to 4-N-trimethyllyamino butyric acid (Rebouche & Engel 1980). However-, only the liver, 
kidney, and brain can convert 4-N-trimethyllyamino butyric acid to carnitine. This is 
because the enzyme that catalyzes the final step, butyrobetaine hydroxylase, is only present 
in these three tissues. Therefore, carnitine must be transported to those tisues that do not 
have the final enzyme. 
Camitine Functions 
The main function of carnitine is the transport of long-chain fatty acids from the 
cytosol into the mitochondria for P-oxidation to take place. In brief, other possible roles 
of carnitine include the regulation of cellular concentration of free CoA, metabolism of 
branched chain amino acids, removal of short-chain and medium-chain acyl residues 
accumulated in the peroxisomes, initiation of ketogenesis, interaction with membranes to 
alter their physiological functions, prevention of fatty liver development due to 
xenobiotics, and detoxification of some drugs (for reviews on carnitine roles refer to 
Borum 1983; Carter et al. 1995; Frenkel & McGarry 1980; Leibovitz 1984; Leibovitz 
1987; and Famularo, G. & De Simone, C. 1995). 
Carnitine and Drug/Xenobiotic Interactions 
Alcohol 
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It is widely known that chronic alcohol consumption inhibited � -oxidation and 
thus causes fatty infiltration in human and experimental animal livers (Leiber et al 1987). 
Impaired oxidation and/or increased lipogenesis are suggested mechanisms for the malady. 
In additio� ethanol depresses camitine palmitoyltransferase 1 activity, the rate-limiting 
enzyme in the translocation of long-chain fatty acids across the mitochondrial membrane 
(Guzman & Geelen 1988). This inhibition may also contribute to the fat accumulation in 
the liver due to alcohol consumption. Supplementary L-carnitine has been found to inhibit 
alcohol-induced fatty liver (Sachan et al. 1984; Sachan & Rhew 1983). Retardation of 
ethanol oxidation found in rats may be one of the mechanisms for the ameliorating effect 
of camitine (Mynatt & Sachan 1992). Carnitine also delayed ethanol oxidation and 
therefore augmented the half-life of ethanol in broilers (Smith et al. 1994). L­
acetylcamitine and L-camitine reduced the rate of ethanol oxidation in rat hepatocytes 
(Cha & Sachan 1995). The underlying mechanism for these effects of carnitine is that 
camitine competitively inhibits alcohol dehydrogenase when the NAD:acetylcarnitine ratio 
is less than 1 (Sachan and Cha 1994). 
Carnitine appears to offer protection against the toxicity of industrial alcohols such 
as methanol, isopropanol, and ethylene glycol ( a common antifreeze). This is because 
carnitine has been shown to prevent accumulation of these alcohols by enhancing their 
excretion in the urine (Brothers 1989). Carbon tetrachloride administration causes fat 
accumulation in rat liver, which is ameliorated by carnitine supplementation (Sachan & 
Dodson 1992). 
Carnitine may also alleviate the side-effects of adriamycin ( doxorubicin 
hydrochloride), a widely used anti-cancer drug. It has been reported that carnitine 
treatment decreased histopathological changes and ameliorated irregular heart 
performance due to adriamycin (Senekowitsch et al. 1987). Furthermore, camitine 
prolonged the survival rate of mice administered with adriamycin (Strohm et al. 1982). 
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V alproic acid, an anticonvulsant drug, has produced very serious side-effects 
similar to Reye's syndrome (stupor, hyperammonia, coma, and hepatic dysfunction) 
(Gerber et al. 1979). Valproic acid treatment in epileptics lowers the serum free carnitine 
and increases the short-chain acylcamitine concentrations (Rodriguez-Segade et al. 
1989). Carnitine has been found to conjugate with valproic acid and other drugs, such as 
cyclopropanecarboxylic acid and pivalic acid. These conjugates are excreted in the urine 
(Quistad et al. 1986; Vickers et al. 1985). However, in another study with rat 
hepatocytes, glycine, but not L-carnitine, prevented lactic acid dehydrogenase leakages ( an 
indicator of cytotoxic effect) induced by valproate (Vance et al. 1994) 
Carnitine also decreased the toxicity of ifosfamide therapy. Ifosfamide, a drug 
used for cancer chemotheraphy, has been known to cause symptoms such as severe 
decreased in the concentrations oftricarboxylic acid cycle intermediates (succinate, 
fumarate, citrate, and a:-ketoglutarate) in the urine. When rats were supplemented with L­
camitine and later injected with this drug, the rats showed better health and had a lower 
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decrease in intermediary products in the urine. The authors suggested that camitine may 
form a complex with ifosfamide, known as chloroacetylcamitine, that reduces the toxicity 
of the drug (Schlenzig et al 1995). 
AFB1 and Lipopolysaccharide �PS) 
The effects ofL-camitine on AFB 1 binding to hepatic DNA, RNA, and protein are 
shown in Table 2.3. L-carnitine supplemented diet fed to rats decreased the binding of 
AFB1 to liver DNA and RNA 6-h post AFB1 administration (Sachan & Yatim 1992). The 
total amounts of AFB1 present in the liver and kidney were not significantly different 
between the carnitine supplemented and control animals (Table 2.4). However, the 
concentrations of AFB1 were higher in the plasma of carnitine supplemented rats than the 
non-supplemented rats. We had also shown that carnitine ameliorated the earlier signs of 
acute toxicity of AFBi, such as the elevation of total lipid concentration in the liver and 
the decrease in total lipids and triacylglycerol concentrations in the plasma (Sachan & 
Y atim 1992). 
LPS or endotoxin is a constituent of the cell wall of Gram-negative bacteria. 
Injection or infiltration of LPS into the body triggers the prodution of cytokines that may 
result in increased lipogenesis, hypertriglyceridemia, and in severe cases, septic shock. 
Carnitine-treated animals exposed to endotoxin have been shown to have higher survival 
rates (Takeyama et al. 1989), lower plasma triacylglycerol, inflammatory cytokines levels, 
and fat synthesis in their livers (Gallo et al. 1993; Winter et al. 1995). 
TABLE 2.3 
Effects of L-camitine supplement on atlatoxin B1-macromolecules adducts 
formation in rat liver 6-h post-atlatoxin B1 administration
1 
Group 
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Parameter Control L-Camitine2 Different (%) 
pmollmg macromo/ecu/es3 
6. 8 ± 2.8a 4.7 ± 2. 9b 
2 1 . 6  ± 0. 3a 1 4. 3  ± 0. 5b 
AFBi-Protein 1.2 ± o.r 1 . 2  ± O.la 
1V alues are mean ± SEM, n = 5. 
2Diet contained 0.4% L-carnitine (w/w) and given to animals for 6 weeks. 
3Different letters indicate significant difference between groups (p < 0.0 5). 
30.9 
3 3 . 8  
0 
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TABLE 2.4 
Tissues and plasma (3H] atlatoxin B1 concentrations in rats supplemented with L­
camitine 6-h post-aflatoxin B1 administration
1 
Group 
Control L-Camitine2 
Liver, nmol AFB1 lg3 3 . 81 ± 0. 28a 3 . 2 5  ± 0. 28a 
Kidney, nmol AFB1 lg 0. 68 ± 0.08a 0. 6 6 ± 0.07a 
Plasma, nmol AFB 1 /di 2 47 ± 1 4a 3 10 ± 41b 
1V alues are mean ± SEM, n = 5 .  
2Diet contained 0. 4% L-carnitine (w/w) and given to animals for 6 weeks. 
3Different letters indicate significant difference at p < O. 05 
Different (%) 
1 4.7  
2. 5 
2 5 . 8  
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Apoptosis 
The effect of carnitine on "programmed" cell death (apoptosis) has been studied. 
When carnitine and its analogs were incubated in C2. 8 hepatocytic cell line incubation 
mixture, the survival and growth rates of the cell were enhanced (Revoltella et al. 1994). 
Cami tine also delays the onset of apoptosis induced by the deprivation of hepatocyte 
growth factor, a factor necessary for the cell growth and survival. In another study 
involving P 19 teratoma cells, acetylcarnitine prolonged cell survival time and delayed 
DNA fragmentation and nuclear condensation caused by serum deprivation (Galli & 
Fratelli 1993). These findings suggest that carnitine may serve as a cytoprotective 
biomolecule; that is, it buffers the impact of certain harmful agents or conditions. 
Cytochrome P450 (CYP) 
CYP is a group of iron-containing enzymes important in the metabolism 
(oxidation) of various endogenous (fatty acids, bile acids, steroids, biogenic amines, 
prostaglandins, and leukotrienes) and foreign compounds ( drugs, environmental 
pollutants, alcohol, and natural plant products). Its name derives from the maximum 
absorption wavelength (450 nm) produced when CYP is reacted with carbon monoxide. 
It is found in the microsomes or the endoplasmic reticulum (ER) of the cell. CYP is 
isolated by homogeniz.ation of the liver and followed by ultracentrifugation of the 
postmitochondrial supernatant fraction. There are two types of ER, rough and smooth, 
which are differentiated by the presence or absence of ribosomes, respectively. The 
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smooth ER has higher oxidative activity of CYP than does rough ER. The organs where 
CYP is found include skin, liver, kidney, testes, ovaries, bladder, aorta, placenta, lung, 
nasal mucosa, blood platelets, gastrointestinal cells, and lymphocytes (Hodgston & Levi 
1994). 
There are about 67 different isoenzymes ofCYP families 1, 2, and 3 (CYPl, 
CYP2, and CYP3) that participate in the biotransformation of toxic materials (Netter 
1994). The metabolism of xenobiotics by CYP enzymes can either activate the 
compounds to become carcinogens or detoxify the compounds. The reactions that CYP 
catalyzes include epoxidation, hydroxylation, dealkylation or 0-demethylation, oxidative 
deamination, oxidation, and desulfuration. 
Glutathione S-Transferase and Glutathione 
Glutathione S-transferases (GST) are a group of enzymes found in liver, kidney, 
lung, spleen, small intestine, brain, heart, ovary and testes (Kraus & Kloft 1980). One of 
GST's primary functions is the metabolism of drugs and xenobiotics, that is, catalyzing the 
conjugation of reduced glutathione ( GSH) to the electrophilic center of the foreign 
compounds. This conjugation is the initial step in the synthesis of mercapturic acid. GST 
has many isozymes, and in mammalian species the isozymes are being classified as alpha 
(intermediate molecular weight), mu (highest molecular weight), and pi (lowest molecular 
weight) (Dauterman 1994). 
Glutathione is the most abundant (> 900/o) intracellular non-protein thiol in animal 
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organs. It is a tripeptide made-up of glutamate, glycine, and cysteine. In mammalian 
livers, GSH represents more than 95% of total glutathione concentration ( 4 to 8 mM), the 
rest being oxidized glutathione (GSSH). GSH plays an important role in regulation of 
enzyme activities by disulfide (thiol) exchange and binding of proteins. In liver cells, most 
of GSH is found in the cytosol and about 10- 15% is found in the mitochondria. 
Besides conjugating to reactive xenobiotics, glutathione is also involved in other 
cellular defense mechanisms such as detoxification of lipid peroxides and free radicals, 
regulation of protein synthesis, and maintenance of immune function (Vina 1990). 
Depletion of GSH can be directly due to conjugation to electrophiles or inhibition of GSH 
synthesis. Decreased level of GSH has been correlated to the pathogenesis of liver 
disease, AIDS, and cataracts. Low cellular concentration of GSH is dangerous since that 
increases the susceptibility of the cell to injury due to toxic challenge ( see Figure 2. 7 for 
GSH homeostasis). Carbon tetrachloride, bromobenzene, and acetaminophen are a few 
examples of compounds that can deplete tissue levels of GSH (Reed 1994 ). 
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FIGURE 2. 7 Changes in glutathione homeostasis by chemical compounds and AFB 1 • 
Source: Reed, D.J. ( 1 994) Mechanisms of chemically induced cell injury and cellular 
protection mechanisms. In: Introduction to Biochemical Toxicology (Hodson, E. & Levi, 
P.E. ,  eds.), pp. 265-296. Appleton & Lance, Norwalk, CT. 
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CHAPTER 3 
Effects of L-Camitine Dosage on Aflatoxin B1-Macromolecule Adducts Formation, 
Glutathione S-Transferase Activity, Glutathione Contents, and Aflatoxin B1 Uptake 
in Freshly Isolated Hepatocytes 
Introduction 
Aflatoxin B 1(AFB 1) is a well known potent hepatotoxic (O'Brien et al. 1983) and 
hepatocarcinogenic (Adamson et al. 1976) mycotoxin. It has been frequently found to 
contaminate many foods such as com, barley, rice, peanuts, and peanut butter. Once 
AFB 1 is consumed, it is easily absorbed in the small intestine and goes into the liver via the 
portal vein. In the liver it then undergoes several biotransformational pathways that 
produce the reactive AFB 1-8,9-epoxide or the less toxic hydroxylated metabolites 
(reviewed by Eaton et al. 199 4). 
AFB i-epoxide is the ultimate carcinogen that covalently binds to cellular 
macromolecules, namely protein, DNA, and RNA. The covalent bindings are the means 
by which AFB 1 exerts its toxic and carcinogenic effects. AFB i-epoxide may also undergo 
detoxification by conjugating to reduced glutathione ( GSH), a process catalysed by 
glutahione S-transferase (GST). This conjugation is the principal detoxification pathway 
of AFB1-epoxide in many mammals. The cytosolic GST activity has been correlated to 
susceptibility of several animal species to AFB 1 carcinogenicity ( Eaton & Gallagher 
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1994). 
L-camitine, 3-hydroxy-4-N-trimethylamino butyric acid, is an important 
biomolecule for the intramitochondrial translocation of long chain fatty acids and many 
other emerging roles in health and disease (Ferrari et al. 1992). We reported earlier that a 
0.4% carnitine supplemented diet fed to rats decreased the binding of AFB1 to hepatic 
DNA and RNA 6 h and 24 h post-AFB1 administration (Sachan & Yatim 1992). The 
AFB1 dose (1 mg/kg) was given orally, 6 week after the animals were started on the diet. 
Camitine significantly reduced AFB1-protein adduct formation 24 h after the AFB1 dose. 
Carnitine supplementation also prevented hepatic steatosis and hypolipidemia caused by 
AFB1 . 
Therefore, the primary objective of this study was to understand the mechanisms 
by which carnitine modulated the AFB1-DNA adducts formation. Since it was decided to 
use freshly isolated rat hepatocytes, we first investigated the effect of carnitine on AFB1-
macromolecules adducts formation in these hepatocytes. The possible role of carnitine in 
inducing the activity of GST and increasing total glutathione concentration were studied 
since GST and glutathione are involved in the detoxification of activated AFB1 . The 
uptake of AFB1 by hepatocytes in the presence of carnitine was also investigated because 
if carnitine could reduce the cellular uptake of AF'Bi, that would reduce the exposure of 
macromolecules to AFB1 . 
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Materials and Methods 
Animals 
The research protocol was approved by the Animal Care and Use Committee of 
the University of Tennessee, Knoxville. Male Sprague Dawley rats weighing 300-350 g 
were housed individually in suspended stainless steel cages in a cubicle of an AAALAC 
approved animal facility. The animals were given free access to Teklad 22/5 Rodent Diet 
(W) 8640 (Harlan, Indianapolis, IN) and chlorinated water. 
Liver Perfusion and Isolation of Hepatocytes 
Buffers 
The buffers used for preperfusion, collagenase perfusion and incubation were 
modified Hank's balanced salt solutions as described by Lotlikar et al. (1989). All buffers 
were saturated with 95% 02 + 5 % CO2 gas before use. (Refer to Appendix 1 for 
detailed procedures for liver perfusion and isolation ofhepatocytes). The pre-perfusion 
modified Hank's buffer contained 0.5 mM EGT A, 25 mM HEPES, and 0.5% BSA (added 
prior to perfusion) but had no ca++ or Mg++. The perfusion buffer was a modified Hank's 
buffer having 2 mM CaC12, 0.5 mM EGTA, 25 mM HEPES, 0.5% BSA, and 0.05% 
collagenase (type IV). The solution was saturated with 95% 02 + 5% CO2 gas before 
the addition of BSA and collagenase just prior to perfusion. The incubation buffer was 
similar to the collagenase buffer except it had no collagenase. 
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Liver perfusion 
The perfusion apparatus and procedures used were according to the modified 
methods of Seglen (1976). Rats were anesthetized with metofane (Pitman-Moore, Inc. 
Mundelein, IL) by the open-drop method in a closed jar. The portal vein was cannulated 
and ca++- and Mg++-free (preperfusion) buffer was injected at a flow rate of30 ml/min for 
about I min while the cannula was secured with ligature. The buffer flow was then 
increased to 50 ml/min, and the anterior vena cava was cut to let the perfusate escape. 
After starting the perfusion (2-3 min), the intact liver was carefully removed from the rat 
and placed flat on the perfusion dish for continous perfusion with 500 ml of the 
preperfusion buffer for about IO  min. Then, the collagenase buffer was introduced at the 
flow rate of 50 ml/min for about 10 min. One hundred ml of 0.05% collagenase buffer 
was used and recycled during the course of the perfusion. The liver swelled to about 
twice its original size at the end of the collagenase perfusion. The liver was placed on a 
watch glass containing 5 ml of the incubation buffer (containing 0.5% BSA), and was 
carefully raked with a stainless steel fork to release the cells from the connective tissue and 
vascular stroma. 
Hepatocyte isolation and viability test 
The liberated cells were suspended in IO  ml of ice-cold incubation buffer 
containing 0.5% BSA and were centrifuged at 50 x g for 3 min at 4 °C. The loose cells 
and supernatant were removed. After this time, the cells were placed in an ice-bucket 
(temperature at about 4 °C). The heavy cell pellet was resuspended with 20 ml of 
incubation buffer containing 0.5% BSA and centrifuged as above. The supernatant and 
loose cells were discarded. These steps were repeated two more times to ensure maximal 
removal of dead cells and other cells (macrophage and fat cells). The hepatocyte pellet 
was suspended and made up to a 20 ml suspension with the incubation buffer containing 
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0.5% BSA. For viability test, the hepatocyte suspension was diluted 1 :  10, and 100 µI of 
the diluted cells were added to 100 µI of0.6% trypan blue and counted using a 
hemacytometer ( see details in APPENDIX 1 ). 
Hepatocytes incubation 
The hepatocytes incubation was done according to the method by Lotlikar et al. 
(1 987). In brief, the incubation mixtures contained 4 x 1 06 cells/ml, modified Hank's 
buffer (pH 7.4) containing 2 mM CaC12, 25 mM HEPES, 0.5% bovine serum albumin 
(fatty acid-free), various levels of L-carnitine (0 - 1 .5 mM), and 0.5 µM [3H]AFB1 (0.5 
µCi/ml). [3H]AFB1 was dissolved in dimethylsulfoxide (DMSO), and the final 
concentration of DMSO was 2%. The incubation medium was saturated with 95% 02 + 
5% CO2 gas before addition to the mixtures. The incubation volume was 5 ml, and 
incubation was conducted in duplicates or triplicates in Erlenmeyer flasks. Carnitine was 
preincubated for 1 5  min before adding the [3H]AFB1 and incubated further for 60 min. At 
the end of incubation time, the flasks were immediately dipped into an ice-water bath 
before further manipulations were carrired out. 
Extraction and Isolation of Macromolecules 
The extraction and isolation of DNA, RNA, and protein were carried out 
according to Glazer's & Weber's ( 197 1) method (Appendix 2). Briefly, the homogenized 
hepatocytes were treateded with perchloic acid (PCA) to precipitate the macromolecules, 
and were centrifuged at 2700 x g for 1 5  min at 2 °c. The pellet was treated with 
potassium acetate, chloroform: ethanol, and absolute ethanol to remove lipids. The pellet 
was resuspended with PCA, left overnight, and centrifuged. The supernatant contained 
RNA. The pellet was resuspended in PCA and heated at 70 °C for 20 min. After 
centrifuging, the supernatant (DNA fraction) was collected. The pellet was washed with 
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double deionized water (DOW) and was centrifuged. The pellet containing the protein 
fraction was suspended by adding potassium hydroxide and heating at 70 °C for 15 min. 
In experiments where only DNA was extracted, the procedures of Gross-Bellard et 
al. (1973) were followed (Appendix 3). In short, at the end of the incubation period, the 
hepatocytes were centrifuged at 500 x g for 5 min to sediment cells. The supernatant was 
discarded. The cells pellet was suspended with 0.3 ml digestion buffer (containing 
IOOmM NaCl, I O  mM Tris-CI, pH 8.0, 25 mM EDTA, pH 8.0, 0.5% SDS, and 0. 1 mg/ml 
proteinase K) and incubated at 50 °C in a  shaking water-bath for 12-18h. Then, 0.3 ml 
digestion buffer (without proteinase K) was added and mixed. DNA was extracted with 
0.6 ml ofphenol:chloroform:isoamyl alchohol (25:24: 1), and was centrifuged at 1700 x g  
for 10 min. To the aqueous layer 250 µI of3.0 M sodium acetate and 1 ml of 100%, 
alcohol were added. After centrifuging at 1700 x g for 2 min, the supernatant was 
discarded, and the pellet was washed with 70% EtOH. The pellet (crude DNA) was dried 
in a "Speedvac Concentrator" for I min, suspended in 1 ml of 10 mM Tris-CI (pH 7.4) 
containing lmM EDTA, and was shaken to aid solubilization at room temperature or at 65 
0c for several hours. 
RNA was removed by adding 0. 1 % SDS and 1 µg/ml DNAase-free RNase and 
incubated at 37 °C for 1 h. DNA was again extracted as described above and solubilized 
in I ml of IO mM Tris-Cl (pH 7.4) containing lmM EDTA. 
The content of DNA was determined colorimetrically using calf thymus DNA as 
standard (Ceriotti 1952) (APPENDIX4). The RNA was measured 
spectrophotometrically using yeast RNA as standard at 260 nm (Glazer & Weber 197 1). 
Protein was measured by the method of Lowry et al. ( 1951) (APPENDIX 5). 
f HJAFB 1 radioactivity measurement 
Radioactivity or disintergration per minute (DPM) was measured by transfering 
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0.5 ml of DNA, RNA, and protein extracts into scintillation vials, added with 5 ml 
Aquasol-2 (Dupont-NEN Research Products, Boston, MA) and counted in a liquid 
scintillation counter (LS-3801 Beckman Instrument, Irving, CA) for 10 min. For protein, 
0 .1 ml of glacial acetic acid was added to decrease random coincidence monitor (RCM) 
before counting. 
Determination of GST activity 
Cytosolic GST activity was determined according to the method by Habig et al. 
(1974) (see Appendix 6 for complete procedures). In brief: the incubation mixture was 
homogenized in 3 complete strokes in a Potter-Elvehjem homogenizer. The cell 
homogenate was centrifuged at 9,000 x g for 15 min in a swinging bucket. The 
supernatant was centrifuged at 100,000 x g for 60 min and the resulting supernatant 
(cytosol) was assayed for GST activity. The changes in absorbance of the reaction 
mixture containing the cytosol minus blank were monitored at 340 nm at 25 °C for 3 min 
in an Hitachi U-2000 double-beam spectrophotometer. The results were reported as µmol 
S-(2, 4-dinitro-1-benzyl)glutathione formed /mg cytosolic protein/min. The cytosolic 
protein content was assayed according to Lowry's method (1951), using BSA as standard. 
Determination of total glutathione concentration 
Total glutathione was assayed according to the method of Griffith ( 1985) as 
described by Anderson (1985) (Appendix 7). After incubation, 100 µI of incubation 
mixture was transferred into microcentrifuge tubes containing 100 µI of 1 O mM HCI. The · 
cells were lysed by freezing in liquid nitrogen and thawing four times. After centrifuging 
at 10,000 x g for 5 min, 100 µI of the supernatant was added with 50 µl 10% sulfosalicylic 
acid to precipitate protein. The protein-free supernatant (25 µI) was mixed with 0.2 mM 
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NADPH, and 0.6 mM 5,5'-dithiobis-{2-nitrobenzoic acid (DTNB), and preincubated at 37 
�C for 3 min. Then 1.3 - 2.6 U glutathione reductase was added to start the reaction. The 
rate of change of absorbance was monitored for 3 min. The concentration of total 
glutathione was calculated from a standard curve using known concentrations of GSH. 
Determination of uptake of AFB 1 by hepatocyes 
After incubation with carnitine and [3H]AFBi, the hepatocytes were separated 
from the incubation medium by centrifugation at 500 x g. After washing the cells with 
incubation buffer (no BSA), the cells were again centrifuged, resuspended, homogenized, 
and centrifuged at 600 x g for IO  min to pellet the nuclei. The post-nuclear supernatant 
was separated from the nuclear pellet. The nuclear pellet was suspended in incubation 
buffer. The incubation medium, washed cells suspension, nuclear pellet suspension, and 
post-nuclear supernatant were extracted with chloroform:ethylacetate (I : I )  to remove free 
AFB1 • Aliquots of these extracted fractions were measured for radioactivity (DPM) in a 
liquid scintillation counter for IO  min. 
Statistics 
All data were expressed as group mean ± SEM. The data were analyzed using 
regression procedure of SAS (SAS Institute, Inc., Cary, NC). The regression curve was 
plotted using Excel 5. 0 software for Windows. The minimum level of significance was set 
atp s 0.05. 
Results 
AFB rMacromolecules Adducts Formation 
Regression analyses were used to examine the correlations of L-carnitine 
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concentrations on AFB1 binding to DNA, RNA and protein of isolated hepatocytes. As 
shown in Figure 3.1, as the concentrations of camitine increased from 0-400 µM, the 
concentrations of AFB1-DNA adducts were linearly decreased in the cells (r = -0.52;p = 
0.039). In the next experiment, a higher range of camitine concentrations (0-1 500 µM) 
was preincubated with the hepatocytes to raise the intracellular camitine concentrations 
that would affect the DNA adducts formation. When higher levels of camitine were 
tested, the correlation of carnitine and DNA adducts was stronger (r = -0.68 1 ), and the 
significance level was better (p = 0.0002) (Figure 3.2). The carnitine effect on the DNA 
adducts formation seems to have flattened at the carnitine concentrations from 1200 µM 
to 1500 µM. As a result, 1200 µM concentration was used in experiments where a single 
concentration of carnitine was required, such as experiments described in Chapter 4. 
Carnitine did not affect the AFB1-RNA adducts formation (Figure 3.3) in the 
hepatocytes. The concentrations of AFB1-RNA adducts remained unchanged as the 
concentrations of carnitine were increased. However, as for AFB1-protein adducts, 
regression analysis shows that carnitine had a significant positive correlation (r = 0.5845; p 
= 0.0 17) on the protein adducts production (Figure 3.4). These RNA and protein 
adducts results are different from what were found in the in vivo study (Sachan & Yatim 
1992). In rats, carnitine supplementation significantly decreased the binding of AFB 1 to 
liver RNA (and DNA), but did not affect on binding to liver protein at 6-h post AFB1 
adrninisteration. 
Effect of carnitine on glutathione S-transferase activity (GST) and total glutathione 
(GSH + GSSH) 
GST is an important detoxification enzyme that catalyses the conjugation of AFB1-
epoxide to GSH. Figure 3.5 illustrates the effects of camitine on GST activity toward 1 -
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chloro-2,4 dinitrobenzene in hepatocytes exposed to AFB1 . The activity of GST was not 
affected by camitine. However, the total glutathione concentrations were positively 
correlated (r = 0. 4 1 ;  p = 0. 041) to camitine levels added to the hepatocytes (Figure 3.6). 
This indicates that camitine has a protective effect on the decrease in the cellular total 
glutathione contents caused by AFB1 . 
Effect of camitine on uptake of AFB 1 by hepatocytes and cellular compartments 
The entry of AFB1 into hepatocytes and consequently into the nuclei is an 
important determinant for the amounts of AFB1 available for bioactivation and binding to 
macromolecules. Therefore, inhibition of AFB1 entry into the cells may account for the 
lower concentrations of AFB1-DNA adducts in camitine treated animals and hepatocytes. 
However, as shown in Figure 3.7, camitine had no significant effect on the entry of AFB1 
into hepatocytes, nuclei, or post-nuclear supernatant. 
Discussion 
AFB 1-macromolecule adducts formation 
Our previous studies with intact rats showed that carnitine supplementation 
decreased hepatic covalent binding of AFB1 to DNA, RNA, and protein 24-h post AFB1 
treatment. (Sachan & Yatim 1992). The present investigation with freshly isolated 
hepatocytes also showed that an increasing dosage of camitine linearly decreased AFBi­
DNA adduct formation. When higher range of camitine concentrations (0 to 1 . 5 mM) 
were present in the hepatocytes' incubation system, the correlation was stronger than when 
lower range (0 to 0.4 mM) of carnitine concentrations was used. In contrast to the in vivo 
study, camitine linearly increased the AFB1-protein adducts concentration, and had no 
significant effect on AFB1-RNA adduct concentration in isolated hepatocyes. 
35 
-
.!! 30 -
li 
CJ 
C 
• 
� t 
a 
== .· I I I ·e
2s
_ 
• • • 
0 . • e • • • 
C 
';' 20 .9. • 
C 
0 
:i 1 5 
(5 
J 
1 0  � 
y = 0.0014x + 22.232 
r = 0.41 0 
p = 0.041 
• 
• Total Glutathione, nmol/million cells 
• Predicted Total Glutathione, nmol/mill ion 
cells 
- Linear (Predicted Total Glutathione, 
nmol/milllon cells) 
5 -1--------+-------+----------1-------1 
0 400 800 
L-Carnitine (µM) 
1 200 
FIGURE 3. 6 Effect of L-camitine on total glutathione concentration in freshly isolated 
hepatocytes treated with AFB1 (n = 5). 
1 600 
80 
=;: 75 
i 70 
£: 65 
i 6) 
m 55 s. 50 
.f 45 
40 
0 
.§ 
10  
.!! t= - : ;i i  4 � 
� 2 
- 0 
0 
40J 
Medium 
800 
L-Carnltlne (µM) 
Nuclei 
1 200  
400 800 1 200  
L-Carnltlne (µM) 
1 Em  
1 Em  
1 6  
.§ 1 4  
I= 
1 2  
- 1 0  
.!! 
- li 
8 
I 6 4 2 
Cells 
0 -,-----....------+----+-----...... 
0 
.§ 
5 
400 800 
L-Carnltlne (µM) 
Post-Nuclear Supernatant 
1 200  
I 4 � , T + t u :· 
1 Em  
! a J..----+---+-----t----t 
0 400 800 1 200  
L-Carnltlne (µM) 
1Em 
FIGURE 3. 7 Effects ofL-carnitine on [3H]AFB1 entry into isolated hepatocytes and distribution into cellular 
compartments (n = 5). °' 
N 
63 
The covalent binding of AFB1 to DNA is an important step in AFB1 carcinogenesis 
(Eaton & Gallager 1994), and AFB1-protein adduct is currently used to assess human 
exposure to AFB1 (Sheabar et al. 1993; Chang et al. 1 994). Therefore, several follow-up 
experiments were conducted to study the biochemical basis for the carnitine's effects on 
the formation of these two adducts (see CHAPTER 4). 
The protective mechanisms suggested for crocetin (a carotenoid) on the AFB1-
DNA adduct fonnation (Wang et al. 1991a) may also apply for carnitine, that is, carnitine 
may suppress the bioactivation of AFBi, induce the detoxification of activated AFB 1, and 
act as an antioxidant that scavenges AFB1 free radicals or peroxides that are produced 
when AFB1 is metabolized by prostaglandin H synthase and lipoxygenase. Prostaglandin 
H synthase (Lui et al. 1990) and lipoxygenase (Lui & Massey 1992) are the other 
metabolic pathways not involving the cytochrome P450 system that can bioactivate AFB1 . 
Carnitine increased glutathione concentration in the cells treated with AFB1, which is 
similar to the effect of crocetin (and will be discussed later in this Chapter). Carnitine has 
been shown to inhibit formation of oxygen-free radicals and increase the repair rate of 
DNA in human cells (Marini et al. 1990; Monti et al, 1992). 
The elevation of AFB1 binding to protein in the hepatocytes system is an important 
observation. In intact animals, carnitine had no effect on AFB1-protein interaction when 
measured at 6-h after AFB1 administration. However, at 24-h post AFB1 treatment, 
carnitine decreased the AFB1-protein concentration (Sachan & Yatim 1992). One reason 
for this difference may be that in the hepatocytes' incubation medium, 0.5% BSA was 
added to keep the cells intact longer when incubating with noxious agents (Berry et al. 
1991 ). We have found that carnitine enhances the binding of AFB1 to BSA (in the 
presence or absence of microsomes) and to rat plasma protein (CHAPTER 4). The 
higher amount of microsomal-activated AFB1 binding to BSA mediated by carnitine 
would be expected to reduce the amount of activated AFB1 available for binding to DNA. 
This may be a very important mechanism by which camitine decreases the AFB 1-DNA 
adduct concentration in the hepatocytes . Unfortunately, from this experiment we are 
unable to differentiate the protein adducts formed with cellular protein and those formed 
with added BSA. 
GST activity 
64 
The present study found no significant e ffect of carnitine on GST activity toward 
l-chloro- 2,4 dinitrobenzene . This indicates that camitine has no influence on this 
detoxification enzyme activity. Several dietary nutrients, nutritional status, drugs, and 
xenobiotics have been demonstrated to affect GST activity. Vitamin A has been shown to 
induce the activity of GST in liver fractions and thereby enhance the detoxification of 
AFB1-epoxide (Bhattacharya et al. 198 9). However, no difference in the GST M l  
protein concentrations was found in woodchuck hepatocytes treated with AFB1 in the 
presence or absence of vitamin A (Yu et al . 19 9 4). Dietary restriction has been shown to 
inhibit AFB1-DNA adduct because of induction of GST activity toward AFB 1-epoxide 
(Chen et al . 19 9 5). Protein-deficient animals has lower GST activity and AFB 1-GSH 
which resulted in higher AFB1-DNA adduct formation (Mandell et al. 19 9 2). 
Ethoxyquin, an antioxidant, added to the diet ( 0. 4%) and fed to rats inhibited 
AFB1-DNA adduct formation because ofinduction of GST activity (Kensler et al. 1 98 9). 
Another antioxidant, BHA, has been shown to increase the activity of GST, resulting in 
the reduction ofDNA adduct formation (Monroe & Eaton, 198 7) . Oltipraz, a 
chemotherapy drug, has been reported to induce GST activity, which leads to a reduction 
of putative preneoplastic lesions caused by AFB 1 (Primiano et al. 19 9 5). In another study 
the protective role of oltipraz has been shown to be a result of both inhibition of AFB 1 
bioactivation and the induction of GS.T activity in human hepatocyte culture (Langouet et 
al. 19 9 5) . A traditional Chinese herbal drug, dimethyl- 4,4'dimethoxy- 5, 6, 5', 6'-
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dimethylenedioxy biphenyl-2, 2'-dicarboxylate (DDB), also has an inhibitory effect on 
AFB1 binding to DNA. In this case, the effect is due to inhibition of cytocrome P-450 
system by DDB, which results in the production of more hydroxylated metabolites which 
are less genotoxic than the epoxide (Guengerich & Shimada 1991). A more recent study 
has demonstrated a similar effect of DOB-mediated reduction of DNA adduct, where the 
mode of action was through the induction of the GST activity and not the increased in the 
production of hydroxylated AFB1 metabolites (Liu et al. 1995). 
Total glutathione concentration 
GSH is important in cellular defense mechanisms such as detoxification of reactive 
xenobiotics and free radicals, and maintenance of immune function (Vina 1990). About 
97.5 - 98.5% (Griffith 1988) or more than 99.5% (Anderson 1985) of the total glutathione 
(oxidized + reduced glutathione) in tissues is in the form of reduced glutathione (GSH). 
GSH can be formed from oxidised glutathione (GSSG) by the catalytic action of 
glutathione reductase. Depletion of GSH concentration can be due to conjugation to 
electrophiles (e.g. AFB1-epoxide) or inhibition ofGSH synthesis. Low levels of GSH are 
detrimental since that increases the susceptibility of cells to injury due to toxic attack. 
The novel finding of the present study is the ability of camitine to prevent the 
decrease in total glutathione content due to AFB1 in the hepatocytes. This obseivation is 
important since the availability ofGSH is essential for GST to promote AFB1-epoxide 
binding to GSH and therefore spare binding to macromolecules. An increase in total 
glutathione concentration may be indicative of reduced amounts of activated AFB1 
formation in the presence of camitine. If camitine decreased the amount of AFBi­
epoxide, there would be decreased need of GSH for detoxification of the epoxide. It is 
also possible that camitine induces the biosynthesis of glutathione. Additionally, camitine 
itself may conjugate to the activated AFB1 and therefore spare the glutathione. The data 
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to support these hypotheses remain to be determined by additional experiments. 
An anology to the camitine effect on AFB1-DNA adduct formation is the effect of 
crocetin on the same. Crocetin, a carotenoid isolated from the seeds of Cape jasmine, has 
been reported to decrease AFB1-DNA adduct production in both microsomal and cultured 
cell systems treated with AFB1 (Wang et al. 1991a). The crocetin concentrations ofO. l 
and 0.5 mM decreased DNA binding by aproximately 17 to 38%, respectively. Crocetin 
had no effect on AFB1-epoxide production in the microsomal system as quantified by 
AFB1-8,9-dihydrodiol concentration. The protective effects of crocetin on DNA adduct 
formation were related to its role in elevation of cytosolic GSH concentration and GS T 
activity. As for carnitine, it increased total glutathione concentration but had no effect on 
GST activity. 
The protective mechanism of geniposide, a compound isolated from the Rubiaceae 
plant family, is different than that of crocetin. Geniposide decreased cellular GSH and 
GSSG concentrations but induced the activity of of y-glutamyltranspeptidase ( the rate­
limiting enzyme for GSH synthesis) and GST (Wang et al. 1991b). Carbon tetrachloride, 
bromobenzene, and acetaminophen have been found to deplete tissue levels of GSH (Reed 
1994). In hepatocytes culture, acetominophen and AFB1 both deplete GSH 
concentrations (Hayes et al. 1986). In light of these observations, the GSH-sparing effect 
of camitine is important and is a new function of camitine. 
AFB I uptake by hepatocytes 
This study found no significant difference in the uptake of AFB1 by the hepatocytes 
or their nuclei in the absence or presence of different concentrations of camitine. 
However, it is possible that the dose response to carnitine was at the lower end of the 
camitine concentration used in the experiments. This is because there was a steep decline 
in the AFB1 concentration between O and 200 µM camitine doses (FIGURE 3. 7). 
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Additional experiments using O to 400 µM camitine with an increment of 50 µM need to 
be carried out for clarification. 
Conclusion 
The results of this study lead us to conclude that carnitine enhances total 
glutathione concentration and promotes the binding of activated AFB 1 to plasma albumin, 
and that it therefore spares DNA from covalently binding to the activated AFB 1 . 
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CHAPTER 4 
Effects of L-Carnitine on Aflatoxin B1 Bindings to Exogenous DNA and Proteins 
Introduction 
Aflatoxins, a group of secondary metabolites of Aspergillus .flavus and A. 
parasiticus, are commonly found to contaminate food and feed supplies. Consumptions of 
aflatoxins contaminated food have been linked to incidences of human liver cancer (Alpert 
197 1 ;  Yu 1995). Due to mounting evidence, the International Agency for Research on 
Cancer (IARC) has upgraded AFB1 from a Group II to a Group I human carcinogen in 
1993 (IARC 1993). 
Aflatoxin B1 (AFB1) is the most toxic and carcinogenic of all naturally occuring 
aflatoxins. Its metabolite, AFB1-epoxide, possesses hepatocarcinogenic and hepatotoxic 
properties through its ability to covalently bind to cellular DNA and protein respectively. 
The AFB1-DNA adducts formation is a crucial step for AFBi-induced carcinogenesis. The 
DNA adducts concentrations have been correlated to incidences of liver cancer in animals 
(Bechtel 1989) and humans (Groopman et al. 1 988). 
L-Carnitine, 3-hydroxy-4-N-trimethylamino butyric acid, is an important co-factor 
for mitochondrial long chain fatty acid oxidation. We have reported that camitine 
supplement reduced the AFB1 binding to liver DNA and RNA, 6-h after a single oral dose 
of AFBi, in intact rats (Sachan & Yatim 1992). Carnitine has no effect on AFB1-protein 
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adducts formation in the liver. In isolated hepatocytes, increasing concentrations of 
carnitine linearly decreased the binding of AFB1 to DNA (Chapter 3). Therefore, one of 
the objectives of this study was to determine if the effects of carnitine on AFBi-DNA 
adduct formation were a result of microsomal metabolism of AFB1 • Since microsomes 
contain the enzymes that bioactivate AFB1 , the findings of this study were expected to 
elucidate the mechanisms of carnitine-mediated decrease of AFB 1-DNA adduct formation. 
Furthermore, it was deemed necessary to determine the specificity of carnitine effect by 
testing the effect of carnitine analog ( acetylcarnitine ), and carnitine-like substances, 
(choline and glycine) on AFB 1-DNA adducts formation in microsomal systems. 
We had observed that the total amounts of AFBi, 6-h post-dosage, present in the 
liver and kidney were not significantly different between the carnitine supplemented and 
control animals. (Table 2.3). However, the concentration of AFB1 was higher in the 
plasma of carnitine supplemented rats. Further, carnitine ameliorated the earlier signs of 
acute toxic effects of AFBi, such as the increase in total lipids concentrations in the liver 
and the decrease in total lipids and triacylglycerol concentrations in the plasma (Sachan & 
Y atim 1992). The higher amounts of AFB1 in the plasma of carnitine supplemented rats 
were interpreted to indicate that carnitine may inhibit the uptake of AFB1 into the 
hepatocytes. 
AFB1 can readily bind to plasma albumin once it is absorbed from the small 
intestine, and that albumin serves as a major transporter of AFB 1 in blood (Dirr & Scabort 
1987). Since it has been postulated that some bioactivation of AFB1 occurs in the 
intestinal mucosa (Hartiala 1977; Vainio & Hietanen 1979) and blood (Sabbioni et al. 
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1987), albumin could be expected to bind to metabolites of AFB1 as well. The binding of 
AFB1 to albumin after being absorbed has been postulated to be one of the detoxicification 
processes of AFB1 (Hseih & Wong 1994). It was hypothesized, therefore, that carnitine 
may increase the binding of AFB 1 to proteins in the mesentric veins and portal vein blood, 
resulting in decreased availability of AFB1 and its metabolites to bind to hepatocellular 
components. Therefore, the other objectives of this study were to determine the effects of 
camitine on binding of AFB1 to plasma proteins and bovine serum albumin with and 
without microsome. 
Materials and Methods 
Animals 
The research protocol was approved by the Animal Care and Use Committee of 
the University of Tennessee, Knoxville. Male Sprague Dawley rats weighing 300-350 g 
were individually housed in suspended stainless steel cages in a cubicle of an AAALAC 
approved animal facility. The animals were given free access to Teklad 22/5 Rodent Diet 
(W) 8640 (Harlan, Indianapolis, IN) and water. 
Liver Pe,fusion and Microsome Preparation 
Rats were anesthetized with metofane (Pitman-Moore, Inc. Mundelein, IL) by the 
open-drop method in a closed jar. The portal vein was cannulated and and the liver was 
perfused with 100 ml ice-cold physiological saline. The details of the procedure are 
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described in Appendix 8. The perfused liver was mixed with 0. 1 54 M KCl buffer 
containing 0.0 1  M KH2P04 (pH 7.4) and homogenized with 3 complete strokes in a teflon­
glass homogenizer to produce a 25% (w/v) homogenate. The homogenate was 
centrifuged at 10,000 x g for 20 min at 4 °C. The supernatant was centrifuged at 100,000 
x g for 60 min at 4 °C using a Sorvall ultracentrifuge. The microsomal pellet was 
suspended in glycerol:phosphate buffer ( 1 :  1 ,  glycerol: 0 . 1 5 M KH2PO 4 (pH 7. 4). 
Microsomal protein concentration was determined by the method of Lowry et al. ( 1 95 1 ) 
decribed in Appendix 5. 
f HJAFB 1 Binding to Calf Thymus DNA 
The DNA binding method of Allameh et al. ( 1 988) with modifications (Hasler et 
al. 1 994) was followed (Appendix 9). There were four groups in this experiment, Group 
1 had no microsome and no carnitine; Group 2 had no microsome but had carnitine ( 1 .2 
mM); Group 3 had microsome but no carnitine; and Group 4 had both microsome and 
carnitine. Briefly, the microsomal incubation mixtures contained 0. 1 M phosphate buffer, 
microsome equivalent to 1 .  0 mg protein, 1 .2 mM L-camitine or other tested compounds 
(pH 7.0), 2 M NADPH, 2 nmol [3H]AFB1 dissolved in dimethylsulfoxide (DMSO), 0. 1 mg 
calf thymus DNA, and double deionized water (DOW) to make-up a total volume of 1. 0 
ml The samples were incubated at 37 °c for 30 min in triplicates and repeated 5 times 
using freshly prepared microsome from a rat each time. 
At the end of the incubation time, a volume of 5 M NaCl was added to produce a 
mixture containing 1 M NaCl. Two ml of chloroform:isoamyl alcohol (24: 1 ,  v/v) and 0.9 
mg of calf thymus DNA ( as a carrier) were added. The tubes were shaken and 
centrifuged at 1 0,000 x g for 10  min. The DNA fraction (top layer) was again extracted 
with chloroform:isoamyl alcohol, shaken and centrifuged 1 0,000 x g for 10  min. The 
DNA fraction was centrifuged at 1 00,000 x g for 1 h. The supernatant was mixed with an 
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equal volume of95% ethanol and centrifuged at 10,000 x g for IO  min to pellet the DNA. 
The DNA pellet was resuspended in 1 ml ofO. l M NaCl (pH 7.0). The DNA 
concentration was determined colorimetrically according to Ceriotti ( 1952), Appendix 4. 
An aliquot of200 µl of DNA solution was added to 5 ml Aquasol-2 (Dupont-NEN 
Research Products, Boston, MA), and DPM were determined for 10 min in a liquid 
scintillation counter (LS-3801 Beckman Instrument, Irving, CA). 
{3H]AFB1 Binding to Bovine Serum Albumin 
For this study, similar incubation medium and experimental design were used 
as in the AFB1-exogenous DNA adducts formation as described above except that fatty­
acid free bovine serum albumin (BSA) was added in placed of DNA. In brief, after 
incubation, the mixtures were quickly chilled in an ice-water bath and then centrifuged at 
100,000 x g for 1 h at 4 °C to pellet the microsome. The supernatant was extracted with 2 
ml chloroform:ethylacetate (1 :  1, v/v), and centrifuged at 2,000 x g  at 4 °C for 10 min to 
remove free AFB1 • The aqueous (top layer) was transferred to new tubes and extracted 
with chloroform: ethylacetate one more time. Protein concentrations were determined in 
the aqueous (protein) fraction according to Lowry et al . ( 195 1) method. Radioactivity or 
DPM was measured by adding 0.2 ml of the protein fraction in 5 ml Aquasol-2 (Dupont­
NEN Research Products, Boston, MA), with 0.04 ml of glacial acetic acid to decrease 
random coincidence monitor (RCM). 
[3 HJAFB 1 Binding to Microsome 
The incubation medium and procedure were similar to that used in the AFB1 
binding to BSA described above. There were two groups in this experiment, control and 
carnitine groups. The medium contained O . 1  M phosphate buffer, microsome equivalent 
to 1.0 mg protein, 1.2 mM L-carnitine (pH 7.0) for the carnitine group, 2 M NADPH, 2 
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nmol [3H]AFB1 dissolved in climethysulfoxide (DMSO), and DDW to make-up a total 
volume of 1 .  0 ml. 
At the end of the incubation period, the mixture was quickly chilled in an ice-water 
bath and centrifuged at 100,000 x g for 1 h at 4 °C to pellet the microsome. The 
supemant was removed, and the microsomes were then suspended in 1 ml of 1 M KOH. 
The microsomal suspension was extracted with 2 ml chloroform:ethylacetate ( 1 : 1 ,  v/v), 
and centrifuged at 2,000 x g for 10  min to remove free AFB1 . The top (aqueous layer) 
was transferred to new tubes and extracted with chloroform: ethylacetate one more time. 
Protein concentration and radioactivity were measured as described in the earlier 
experiments. 
AFB 1 Non-Covalent Binding to Proteins as Measured by Membrane Ultra.filtration 
Method 
The incubation was done in glass culture tubes. The mixture contained BSA (0.8 
µg) or rat plasma (20 µI equivalent to 0 .8 µg albumin}, with or without 1 .2 mM L­
camitine (pH7.0}, 2 nmol [3H]AFB1 dissolved in DMSO and was made-up to a total 
volume of 300 µI with DDW. The mixture was allowed to stand at room temperature 
( approximately 25 °C) for 1 0  min and then transferred into the upper chamber of a 
prewashed Ultrafree-MC filter unit (Millipore Corporation, Bedford, MA). The nominal 
molecular weight limit of the Ultrafree-MC regenerated cellulose membrane used was 
30,000. Refer to Figure 4.1 for the flow diagram of separation of bound versus unbound 
[
3H]AFB1 to proteins by the modified method ofLipford et al. (1 990). The filter unit was 
then centrifuged at 2000 x g for 20 min. The filtrate was removed, and the concentrate in 
the upper chamber was washed once with 400 µI Hank's buffer and centrifuged again at 
2000 µI for 30 min. The upper chamber that retained the protein was transferred into 
scintillation vials and radioactivity was determined. 
Prewashed Ultrafree filter with 400 µI DDW 
Transfer incubation mixture to top chamber of 
Ultrafree filter unit 
Centrifuge at 2,000 x g for 20 min at 25 °c 
Top chamber 
(400 µI limit) 
Membrane 
Remove filtrate 
Protein 
Concentrate 
Filtrate 
Add 400 µI of buffer to top chamber 
Centrifuge at 2,000 x g for 30 min at 25 °c 
Measure radioactivity in the top chamber that 
contains the protein concentrate 
FIGURE 4.1 Ultrafihration method of determining bound PH]AFB1 
to proteins 
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Statistics 
The values are reported as means ± SEM. Statistical analysis of the data was 
performed using the SAS statistical program (SAS version 6. 1 1 , SAS Institute Inc. ,  Cary, 
NC). The differences between two groups were analyzed by Student's t test. For 
comparison of several groups, general linear model (GLM) procedures or two-way 
crossed ANOV A were used when appropriate. When significant, Duncan's Multiple Range 
test or Contrast statement were used to compare between means. The critical level of 
significance was set at p < 0. 05 . 
Results 
AFB 1-calf thymus DNA adducts formation 
The bindings of AFB1 to calf thymus DNA in the presence or absence of carnitine 
and microsome are shown in Figure 4.2. There were none or very little AFB1-DNA 
adducts formed in the absence of microsome in the incubation mixture, and carnitine has 
no significant effect. In the presence of microsome, there was significantly higher AFB1-
DNA adducts formation in the control (250 pmol/mg DNA) and carnitine (200 pmol/mg 
DNA) groups. This is consistent with the fact that AFB1 has to be metabolized for it to 
bind to DNA. This microsome-mediated AFB1 binding to DNA was significantly lower in 
the presence of carnitine. This indicates that carnitine may alter the bioactivation of AFB1 
(produces less epoxide) and/or affect the binding of AFB1-epoxide to DNA (inhibition of 
AFB1-epoxide electrophilic binding to guanine of DNA). 
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FIGURE 4.2 Effects ofL-carnitine ( 1 .2 mM) on AFB1 -calf thymus DNA adducts formation 
mediated by microsomal enzymes (n =5). Different letters indicate significant difference 
among groups (p < 0.05). 
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Specificity of camitine 
The effects of carnitine, acetylcarnitine, and carnitine-like substances on the DNA 
adducts formation are shown in Figure 4.3. The concentration of AFB1-DNA adducts in 
the control group was 216 pmol/mg DNA. In the camitine, acetylcamitine, and GABA 
groups, the DNA adduct concentrations were 170, 154, and 165 pmol/mg DNA 
respectively. The decreases in DNA adduct in these three groups were significantly lower 
than the control group. This shows that the reduction in the DNA-adducts formation is 
not very specific to carnitine. Choline and glycine had no significant effect on the AFBi­
DNA adduct formation. 
AFB1-BSA Adducts Formation 
The binding of AFB1 to proteins (BSA and microsomal protein) are presented in 
Figure 4.4. In contrast to DNA (Figure 4.2), there was some binding ofunmetabolized 
AFB1 to BSA (13.4 pmol/mg BSA in Group 1, and 16.2 pmol/mg BSA in Group 2). 
These are noncovalent bindings since no microsome was added into the incubation mixture 
to produce the AFB1-epoxide that can bind covalently to macromolecules. Camitine had 
no significant effect ( contrast p value = 0 . 171) on these non-covalent AFB1-B SA bindings 
(Group 1 vs Group 2). 
In the presence ofmicrosome, there were markedly higher amounts of AFB1-BSA 
adduct formed (Group 3 and 4). The BSA adducts formed were 5 .8 times higher in 
Group 3 than in Group 1, and 5 .5 times higher in Group 4 than in Group 2. The higher 
concentrations of AFB-BSA adducts in the presence of micro some were due to both 
covalent and non-covalent bindings. The average amount of covalent AFB1-BSA bindings 
in Group 3 was 64. 1 pmol/mg BSA, and in Group 4 was 72. 7 pmol/mg BSA ( calculated 
by subtracting the adduct concentrations of Group 3 from Group 1, and Group 4 from 2). 
Therefore, covalent bindings constitute the higher portion of the AFB1-BSA adduct shown 
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in Groups 3 and 4. The presence of camitine in the microsome-containing incubation 
mixture significantly increased (p = 0.0005) the AFB1-BSA adducts formation (Group 4 vs 
Group 3). This is an indication that camitine increased the covalent binding of AFBi­
epoxide to BSA. 
AFB rMicrosoma/ Binding 
The concentrations of AFB1 binding to microsomal proteins in the absence or 
presence of camitine are shown in Figure 4.5. Obviously, there was some binding of 
AFB1 to the microsomal component, and camitine significantly increased (p = 0. 007) the 
binding compared to the control. This AFB1 binding to microsomal protein was about 
two times higher than the binding of AFB1 to BSA (Figure 4.4; Groups I and 2). 
AFB 1 Non-Covalent Binding to Proteins as Measured by Ultrafiltration Method 
The data on the binding ofunmetabolized AFB1 to plasma proteins and BSA are 
presented in Figures 4.6 and 4.7, respectively. The camitin_e group had significantly 
higher binding of AFB1 to plasma proteins than the control group (p = 0.022). The AFBi­
BSA adducts formation was also higher in the camitine group than the control group (p = 
0.01 8). Compared to the rat plasma, higher concentrations of the protein adducts were 
formed (approximately 1 59°/c, more in the control groups and 1 75% more in the carnitine 
groups) when the protein was BSA. This is most likely related to the purity ofBSA 
protein as plasma has components other than albumin. 
Discussion 
The experiments in this Chapter were aimed exploring other possible mechanisms 
of camitine-mediated attenuation of AFBi-DNA adduct formation. The data suggest that 
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at least three processes are affected by carnitine. These are: I )  bioactivation of AFB1 and 
binding of activated AFB1 to DNA; 2) binding of AFB 1 to plasma proteins; and 3) 
binding of AFB 1 to microsomal proteins. 
Bioactivation of AFB 1 and binding of activated AFB 1 to DNA 
AFB1 needs to be activated by microsomal enzymes to form the AFB1-epoxide 
which covalently binds to the electrophilic center (N, 0, and S atoms) of cellular 
macromolecules such as DNA, RNA, and protein (Stark 1986). The covalent binding, 
especially to DNA, is the crucial initial step of AFB1 carcinogenesis. 
First of all, the current study, confirms the role of microsomal enzymes in 
producing the metabolites that can bind to DNA. More importantly, this study shows that 
in the presence of camitine, the binding of microsomal activated AFB1 to DNA was 
decreased. This indicates that carnitine interferes with the bioactivation of AFB 1 . 
Microsomes contain the enzymes that biotransformed AFB1 to its activated form (AFBi­
epoxide) and the less toxic hydroxylated metabolites. Therefore, if camitine can affect the 
metabolism of AFB1 that results in lesser production of AFB1-epoxide, then there will be 
lower amount of epoxide for covalent binding to DNA. On the other hand, it may be that 
camitine has no effect on the metabolism of AFB 1 whatsoever, but it simply prevents the 
epoxide produced from binding to DNA. This postulation is made on the basis that 
camitine itself may bind the AFB1-epoxide and therefore limit the amount of epoxide for 
binding to DNA. Carnitine has the quartemary nitrogen group similar to the electrophilic 
center of guanine of DNA and is available for electrophilic attack by AFB1-epoxide. More 
studies are needed to specify which one of the above two pathways is operational. 
The effect of camitine is not highly specific as acetylcamitine and GABA were 
also found to reduce the AFB1-DNA adduct formation to about the same degree as 
carnitine. Two other compounds structurally related to camitine, choline and glycine, had 
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no significant effect on the binding of AFB1-epoxide to DNA. The analogy with GABA in 
this regard is quite interesting for studying the receptor-mediated mechanism of camitine 
effect. 
The lack of choline effect is not entirely surprising as choline effect is highly 
controversial. It has been reported that choline-deficiency had no effect on the liver 
AFB1-DNA adduct concentration in rats given a single dose of AFB1 . However, when 
multiple doses of AFB 1 were given, the DNA adduct formation was markedly elevated in 
the choline-deficient animals (Schrager et al. 1990). On the contrary, an earlier report 
indicates that a diet marginally deficient in lipotropes (methionine, choline, and folacin) fed 
to rats which were given a single dose of AFB1 suppressed DNA adduct formation in the 
liver (Campbell et al. 1978). Yet another recent study demonstrated that a choline­
methionine deficient diet, fed to rats, had no significant effects on serum biochemical 
parameters and liver pathology due to a dose of AFB1 (Mehta et al. 1993). 
Binding of AFB 1 to proteins 
AFB1 and its metabolites, particularly AFB1-epoxide, are known to bind to plasma 
protein (Chu 1994 ), and this binding may be altered by pH and fatty acid concentrations 
(Dirr 1989). Camitine significantly increased the covalent binding of microsomal activated 
AFB1 to BSA, a purified form of serum protein (FIGURE 4.4). It also increased the 
binding of non-metabolized AFB1 to BSA and plasma proteins (FIGURES 4.6 and 4.7). 
The binding of AFB1 was nearly six times higher in the presence of microsome than in 
absence of microsome, suggesting that AFB1 metabolites have a higher affinity for BSA 
and that the effect of carnitine is significant in both cases. 
There are two hypotheses for how camitine elevation of AFB1-protein binding can 
lead to a reduction in AFB 1-DNA binding. First, it is postulated that if carnitine can 
somehow increase the AFB1 retention by plasma proteins, less will be available for uptake 
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by hepatocytes. When the uptake of AFB1 is reduced, less AFB1 will be ·available for 
metabolism in the liver cells to cause harmful physiological changes. It has been suggested 
that since the liver has high capability to draw free AFB1 from the blood, AFB1 binding to 
plasma albumin once it is absorbed from the intestine can be one of the detoxification 
processes of AFB1 (Hsieh & Wong 1994). Plasma contains about 7-8% proteins, and 
albumin constitutes about 50-60% of plasma proteins (Anderson & Lunden 1979). 
Albumin has been shown to be the main plasma protein that binds AFB 1 and therefore to 
serve as the major transporter of AFB1 in the blood (Dirr & Schabort 1987). It was 
demonstrated that almost all (> 95%) of the AFB1 found in rat plasma proteins was 
noncovalently bound, and about 800/o of AFB1 was found in the albumin fraction 
(Ewaskiewicz et al. 199 1). So the albumin serves as the transporter of AFB 1 in the 
plasma, and carnitine is a positive effector. 
Second, since carnitine increases the covalent binding of AFB 1 to plasma protein, 
it is possible that carnitine can also increase the covalent binding of AFB 1 to cellular 
protein and therefore reduce the binding of activated AFB1 to cellular DNA. We were 
unable to study this for technical reasons. 
The above AFB 1-albumin data raise an important implication, since AFB1-albumin 
adduct concentration in plasma has been widely used as an acceptable biomarker in 
evaluating exposure of AFB1 in humans (Chang et al. 1 994). Our :findings invoke a special 
caution that should be taken when interpretating the results of AFBi-albumin data. Higher 
concentrations of AFB1-albumin adduct in the blood may not always indicate higher intake 
of AFB 1 but may be a consequence of modulation by dietary nutrients such as camitine 
and others yet to be identified. Dirr (1987) reported that the increase in plasma 
concentrations of long chain fatty acids considerably increased the AFB1-plasma albumin 
concentration. This is besides the fact that AFB 1 binds to serum albumin and hepatic 
DNA in a dose-dependent manner (Sabbioni et al. 1990). 
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Binding of AFB 1 to microsomal proteins 
From this rather indirect determination, it is extrapolated that carnitine increases 
binding of AFB 1 to the microsome. This is supported by the fact that AFB1 has been 
shown to have highest affinity for liver microsoine followed by the cytosol, mitochondria 
and nuclei (Ewaskiewicz et al. 1991). 
Conclusion 
The protective mechanisms of carnitine against the AFB1-DNA adduct formation 
are related to 1)  reduction of AFB1 bioactivation; 2) sequestration of AFB1-epoxide; and 
3) enhancing of the binding of AFB1-epoxide to cellular protein and microsome. 
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CHAPTER S 
Future Research 
The following are some areas for future studies: 
a) Identify the cytochrome P-450 isozyme(s) and quantify the metabolites of AFB1 
that may be affected by carnitine. These findings will show if carnitine has an 
effect on AFB 1 metabolism, especially the production of the AFB 1-epox:ide. 
b) Determine if carnitine can bind to activated AFB1 • The results of this 
experiment will further explain the mechanisms of carnitine reducing the AFB 1-
DNA adduct formation. 
c) Determine the effect of carnitine on AFB1-glutathione conjugate formatio� 
concentrations ofGSH and GSSH, and GSH:GSSH ratio. These data will 
explain how carnitine ameliorated the reduction in total glutathione 
concentration caused by AFB 1 . 
d) Determine the effect of camitine on the AFB 1 binding kinetics (for examples, 
maximum number of binding sites (Bmax) and equilibrium dissociation constant 
(Kd)) to plasma protein (albumin) and cytosolic protein. 
e) Determine the effect of carnitine on the bindings of AFB1 to DNA, RNA, and 
protein when the macromolecules are incubated together in a microsomal 
system. This will provide information about the changes in the binding affinity 
of activated AFB1 to macromolecules in presence of carnitine. 
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APPENDIX 1 
Isolation and Preparation of Hepatocytes 
Buffers for Pre-Perfusion, Perfusion and Incubation 
Table I shows the buffers used for preperfusion, collagenase perfusion and 
incubation. The buffers were modified Hank's balanced salt solutions as described by 
Lotlikar et al. ( 1 989). The pre-perfusion modified Hank's buffer contained 0.5 mM 
EGTA, 25 mM HEPES, and 0. 5% BSA (added prior to perfusion) but had no ca++ and 
Mg++. The solution was saturated with 95% 02 + 5 CO2% gas before used. The 
perfusion buffer contained modified Hank's buffer having 2 mM CaC12, 0.5 mM EGTA, 
25 mM HEPES, 0.5% BSA, and 0.05% collagenase (type IV). The solution was 
saturated with 95% 02 + 5 CO2% gas before the addition of BSA and collagenase just 
prior to perfusion. The incubation buffer was similar to the collagenase buffer except it 
had no collagenase. 
Perfusion Apparatus 
The perfusion apparatus utilized were similar to that described by Seglen (1 976). 
It consisted of : 
a) a water-jacketed coiled glass tube (2 x 4 mm glass tube with 22-24 coil ( coil diameter 
30 mm; coil length 100mm) connected to a water bath that maintained the buffer 
temperature at 37°C. 
b) a filter and bubble trapping unit that prevented any bubbles from entering the liver 
during perfusion. 
c) an adjustable flow pump unit that pumped the buffer from the buffer flask through the 
coiled glass tube and flowed into the filter and bubble trapping at certain flow rate. 
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d) a canula tube that connected to the filter and bubble trapping unit. 
Table I The compositions of the buffers were as follows : 
Chemicals ca++_ and I Col/agenase I Incubation ! I 
(mw'L) Mg++-free ' buffer buffer 
buffer 
CaCl, - 222 222 
MgS04. 7H20 - 200 200 
KCl 400 400 400 
KH)P04 60 60 60 
NaHCO� 350 350 350 
NaCl 8000 8000 8000 
N�HP04.H')O 60 60 60 
Glucose 1000 1000 1000 
EGTA 190 - -
HEPES 5,958 5,958 5,958 
pH 7.4 7.4 7.4 
10% BSA (ml/L) - 50 50 
Collagenase - 500 -
Needed (mVperfusion) 500 100 250 
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e) a 95% 02 and 5% CO2 gas tank. 
Surgery and Perfusion Procedure 
a) Rat was anesthetized with metofane (Pitman-Moore, Inc. Mundelein, IL) by open-drop 
method in a closed jar. 
b) The anesthetized rat was placed on an operating tray on its back. When needed, 
metofane in a 10 ml scintillation glass bottle was placed to cover the nose of the 
rats to continue anesthesia of the rat. 
c) A cut was made from the middle of lower end of the abdomen to the upper end of the 
abdomen just below the diaphragm. 
d) A V-shaped cut was made below the ribs that went to the left and right ribs. 
e) The intestine was carefully moved to the left side of the abdomen to exposed the portal 
vem. 
t) Two loose ligatures (about 5 mm apart) were placed around the portal vein about 1-2 
mm away from the liver. 
g) The Ca++- and Mg++-free buffer was tum on at a flow rate of 30 ml/min. This buffer 
was continually saturated with 02 gas and the temperature were set at 37 °C. 
h) A small cut was made just below the furthest ligature from the liver, cannula tube (with 
the buffer flowing) was inserted through the cut, and the ligatures were tightened. 
i) The perfusion flow was increased to 50 ml/min and the posterior vena cava was cut to 
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the let the perfusate to escape. 
j) After about 2-3 min, while the perfusate still flowing the liver was removed from the rat 
by cutting all the attachments to the liver and placed flat as the in situ position on 
a perfusion dish. 
k) When the 500 ml ofCa++-free buffer was about finished (10 min.), the buffer flow was 
stopped, changed the buffer reservoir to the collagenase buffer in a 250 ml beaker, 
placed the liver dish on top of the 250 ml beaker, and started the buffer flow at 50 
ml/min for about IO min. The liver swelled to about twice its original size. 
l) The liver was placed on a watch glass, added with 5 ml of the incubation buffer 
containing 0.5% BSA, and the liver was carefully raked with a stainless steel fork 
to release the cells from the connective tissue and vascular stroma. 
Cell Purification and Viability Test 
a) The liberated cells were suspended in IO ml of ice-cold incubation buffer containing 
0.5% BSA, and was centrifuged at 50 x g for 3 min at 4 °C. The loose cells and 
supernatant were removed. After this time, the cells were placed in a ice-bucket 
(temperature at about 4 °C) when they were not being manipulated. 
b) The heavy cell pellet was resuspended with 20 ml of incubation buffer containing O. 5% 
BSA, and centrifuged as above. The supernatant and loose cells were discarded. 
c) Step 4 b was repeated 2 more times to ensure maximal removal of dead cells and other 
cells (macrophage and fat cells). 
d) The hepatocytes pellet was suspended and made-up to 20 ml suspension with the 
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incubation buffer containing 0.5% BSA 
e) For viability test, the hepatocyte suspension was diluted 1 :  10, and I 00 ml of this diluted 
cells was addded to I 00 ml of O. 6% trypan blue ( therefore, the dilution factor 
=20). The cells were counted from 4 outer squares in a hemacytometer, by an 
Olympus T041 microsope. 
t) Calculation: 
Cells/ml = Average # cell x D.F. x Factor for vol. of cell suspension under cover slip 
(10-4 ml) 
:. Cells/ml = (Total # cells/4) x 20 x 104/ml. 
APPENDIX 2 
Composition of Hepatocyte Incubation Mixtures and Detemination of AFB1-
Macromolecule Adducts Formation 
A. Incubation Mixture (in duplicate or triplicate) 
I IO x I 06 cell/ml, ml 
2 L-Carnitine ( I 0 
mM, 
pH 7.0), µI 
3 Hank's Buffer 
(+ 0.5%BSA), µI 
4 DOW, µl 
5 DMSO, µI 
6 [H3]AFB1 
(0. l mCi/umol), µl 
TOTAL, ml 
B. Incubation Procedures 
GrQJ.112 I 
O CNE 
2 
--
2 130 
750 
1 00 
20 
5 
I 
GrQYl2 2 
0.2 mM 
CNE 
2 
1 00 
2 130 
650 
1 00 
20 
5 
' Groug 3 
0.8 mM 
CNE 
2 
i, 
l 
400 
2 130 
350 
1 00 
20 
5 I 
GrQU12 4 
1 .2 mM : 
CNE 
2 
600 
2130 
1 50 
1 00 
20 
5 
Groug 5 
l . 5 mM 
CNE 
2 
750 
2 130 
0 
100 
20 
5 
I l l  
I .  Add hepatocytes, L-camitine, HB, and DOW (but not DMSO and [H3]AFB1) in 25 
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ml Erlenmeyer flasks. 
2. Mix the mixtures by swirling the flasks. 
3. Flush the flasks (without touching the incubation mixture) with 02:C02 (95%: 5%) for 
30 sec, and seal with rubber stoppers. 
4. Incubate at 37 °C for 10 min a shaking water bath (speed 75-80 rpm which is about 
3 .5  of the water bath knob scale). 
5. Mix [H3]AFB1 and DMSO together, and add them to the incubation mixture. 
6. Mix by swirling the flask. 
7. Flush the flasks (without touching the incubation mixture) with 02 :C02 (95%:5%) for 
1 min, and seal with stopper. 
8. Incubate at 37 °C for 60 min in a shaking water bath (speed 75-80 rpm). 
9. Place the flasks immediately into an ice-water bath to stop the reaction. 
10. Transfer 100 µI ofTh1 into microcentrifuge tubes containing 100 µl of 10 mM HCl for 
Total GSH determination, 0.5 ml into another tubes for GST activity assay ( 2  x 1 06 
cells contain 5-8 mg protein; needed 1 mg protein), 3 ml into another tubes for DNA 
determination, and 300 µI into another tube for polar and non-polar metabolites 
extraction and quantitation. Transfer also the remaining of IM into new tubes. 
11. Quickly freeze all tubes in liquid nitrogen, and store tubes at -80 °C until use. 
C. Macromolecules Extraction, Quantitation, and AFB rmacromolecules Determination 
1 .  Centrifuge the tubes (from step B 1 0) at 500 x g for 5 min to sediment cells. Discard 
SN. 
1 13 
2. Wash the cells with 1ml of ice-cold incubation buffer (no BSA). Suspend cells by 
gentle mixing. Centrifuge. Discard SN. 
3. Repeat step 2. 
4. Resuspend cell in 4 ml of incubation buffer. 
5. Homogenized cells with 3 complte strokes in a teflon-glass homogenizer. 
6. Transfer 3 ml of homogenized cells and add 3 ml of ice-cold 1.0 PCA. 
7. Vortex and centrifuge at 600 x g for 10 min at 2 °C. Discard the supernatant. 
8. Wash pellet with 1.5 ml 0.2N PCA and centrifuge at 600 x g  for 10 min. Remove 
supernatant. 
9. Repeat Step 8 for 3 more times. 
1 1. Add 1. 5 ml O . 1  N KAc prepared in absolute ethanol. Vortex, centrifuge at 2000 x g 
and discard supernatant 
12. Add 1. O ml chloroform: absolute ethanol ( 1 :  1, v/v). Vortex, centrifuge at 2000 x g 
and discard supernatant. Repeat once. 
13. Add 1 ml absolute ethanol. Vortex, centrifuge at 2000 x g and discard supernatant 
completely. Air dry or vacuum dry the pellet. 
14. Add 1. 0 ml of 1. SN PCA, resuspend pellet by vortexing, and leave overnight in 
refrigerator (4 °C). 
15. Centrifuge at 2000 x g, collect supernatant. 
16. Wash pellet 2 times with 0.5 ml of0.5N PCA. Vortex, centrifuge, and pool 
supernatant each time into Step 15 tubes. The combined supernatants contain the 
RNA fraction. 
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17. Add 1 ml of O. SN PCA to pellet. Vortex and incubate at 70 °c water bath for 20 min. 
Centrifuge and collect supernatant. 
1 8. Repeat Step 1 8. The combined supernatant contains the DNA fraction. 
19. Wash pellet with DOW twice. 
20. Add 1.0 ml of I .ON KOH to pellet. Vortex and incubate at 70 °C water bath for 15 
min. Centrifuge and collect supernatant. The supernatant contains the protein 
fraction. 
21. RNA is determined the same day spectrophometrically at 260 run using yeast RNA as 
standard. 
22. DNA is determined by Ceriotti method (1952) (APPENDIX 4 ). 
23. Protein is determined by Lowry et al. (195 1) (APPENDIX 5). 
24. To measure radioactivity, transfer 0.5 ml of each RNA, DNA, and protein fractions 
into scintillation vials, add 5 ml of scintillation fluid. For protein samples, add 0. 1ml 
glacial acetic acid. Mix by turning vials, and count radioactivity (DPM) for 10 min. 
APPEND1X 3 
DNA Extraction and Isolation (Genomic DNA Procedure), Quantitation, and 
AFB1-DNA Determination 
1. At the end of incubation time, centrifuge the tubes at 500 x g for 5 min to sediment 
cells. Discard SN. 
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2. Wash the cells with ice-cold 1ml of Hank's buffer (no BSA). Suspend cells by gentle 
mixing. Centrifuge. Discard SN. 
3. Repeat step 2. 
4. Add 0.3 ml digestion buffer (100 mM NaCl, 10 mM Tris-Cl (pH 8.0), 25 mM EDTA, 
pH 8.0, 0.5% SOS, and added fresh 0. 1 mg/ml proteinase K) to pellet. Suspend cells 
by gentle mixing. Tightly cap tubes. 
5. Incubate at 50°C in a shaking water-bath for 12-18h (80-90 oscillations/min). 
6. Add 0.3 ml digestion buffer (without proteinase K), and mix. 
7. Add 0.6 ml of phenol:chloroform:isoamyl alchohol (25:24: I )  to extract DNA. 
8. Vortex, centrifuge at 1700 x g for 10 min. 
9. Transfer 500 ul of the top ( aqueous) layer to new tubes. 
10. Add 250 ul of3.0 M sodium acetate and 1000 ul of 100% alcohol. Vortex. 
1 1. Centrifuge at 1700 x g for 2 min. Discard SN. 
12. Wash pellet thoroughly with 1 ml of 70% EtOH. Centrifuge at 1700 x g for 2 min. 
Discard SN. Dry in a 'Speedvac Concentrator' for 1 min. 
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13. Suspend DNA pellet in 1 ml of 10 mM Tris-Cl (pH 7.4) containing lmM EDTA (TE 
buffer) until dissolve. 
14. Remove RNA by adding 0.1% SOS (10 ul of 10 % SOS) and 1 ug/ml DNAase-free 
RNase (20 ul of 50 ug/ml RNase), and incubate at 37 °C for 1 h. 
15. Add 1 ml of chloroform:isoamyl alchohol (10:2), mix thoroughly. 
16. Centrifuge at 1700 x g for 10 min. Transfer 800 ul of the top layer (aqueous layer) 
into new tubes. 
17. Add 400 ul of 3M sodium acetate and 1 .6 ml 1000/o EtOH. Vortex. Centrifuge at 
1700 x g for 2 min. Discard the SN. 
18. Wash pellet thoroughly with 1 ml of 70% EtOH. Centrifuge at 1700 x g for 2 min. 
Discard SN. Dry in a 'Speedvac Concentrator' for 1 min. 
19. Resuspend DNA in 1 ml of 10 mM Tris-Cl (pH 7.4) containing lmM EDTA. 
(DNA may be shaken gently at R. T. or at 65 °C for several h to aid solubilization) ... 
20. Determine DNA content spectrophotometrically using calf thymus DNA dissolved in 
Tris-EDTA buffer as standards (0.2 to 5 ug/ml) and by Ceriotti method (APPENDIX 
4). 
(Concentration of DNA is approximately 2 mg/g of cells; I g ofhepatocytes contain 
approximately 109 cells) 
21 .  Transfer 0.2 ml of pure DNA extracts into scintillation vials, add 5 ml scintillation 
fluid, and measure radioactivity (DPM) for 10 min. 
22. Store DNA at 4 °C for short-term storage, and at -80°C for long term storage. 
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APPENDIX 4 
DNA Assay 
Procedures: 
1 .  Set the DNA standards and sample tubes as shown below: 
Tube 1 ms/ml DNA TE Buffer o 04% Indole c HCI CHCli mgDNA 
Blank 0 µI 1000 ul 0.5 ml 0.5 ml 2 ml 0 
S I  5 995 0.5 0.5 2 5 
S2 1 0  990 0. 5 0.5 2 IO  
S3 1 5  985 0.5 0.5 2 15 
S4 20 980 0.5 0.5 2 20 
S5 25 975 0.5 0.5 2 25 
S6 30 970 0.5 0 .5 2 30 
Sample 100-200 µl 800-900 0.5 0.5 2 ? 
Sample 20 µl 980 0. 5 0.5 2 ? 
2. Add DNA standards or sample, TE buffer (see APPENDIX 4), and 0.5 ml of 0.04% 
indole. Mix.3 .  Add 0.5 ml concentrated HCI. Mix. 
4. Cover tunes with cap tightly and place in 100°C water-bath for exactly 1 0  min. 
5. Immediately cool tubes by dipping them in a bucket of tap water. 
6. Add chloroform (do this under the hood) and vortex thoroughly. 
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7. Centrifuge at 1700 x g for 10 min. 
8 .  Using clean disposable transfer pipet each time, remove the lower (CHC13) layer . 
9. Repeat steps 6 and 8. 
10. Transfer the top layer into 1 ml disposable cuvet (do not take the lower layer). 
1 1 . Read absorbance at 490 run against the blank. 
12. Construct a standard curve get the linear regression equation. 
0.12 -
·0.1 
t y = 0.0052x + 0.001 6 
E 
o.os 1 R2 = 0.998 C 
0.00 j 
• 
C 
.D. 
0.0
4 I .D. 
0.02 
0 
0 5 1 0  1 5  20 
Calf Thymus DNA. µg 
DNA Standard Curve 
Calculation : µg DNA = Absorbance/Slope x D .F. 
Reference: Ceriotti, G. (1 952) A microchemical determination of DNA. J. Biol. Chem. 
1 98:297-303 . 
APPPENDIX 5 
Protein Determination (Lowry' s Method) 
Reagents 
1 .  2 % (w/v) sodium carbonate (N�C03) in 0. 1 N sodium hydroxide (NaOH). 
Dissolve 6 g N�C03 in O. IN NaOH and mark-up to 300 ml with DDW. 
2. O. IN NaOH. 
Dissolve 2g NaOH in 450 ml DDW and mark-up to 500 ml volume. 
3 .  1% (w/v) cupric sulfate (CuS04.5H20). 
Dissolve 0.5g CuS04.5H20 in DDW and bring up to 50 ml volume. 
4. 2% Sodium potassium tartarate (NAKC4H406.4H20). 
Dissolve lg NAKC4H406 .4H20 in DDW and bring up to 50 ml volume. 
5 .  Diluted F olin reagent. 
1 1 9 
Dilute Folin & Ciocalteu's phenol reagent 1 : 1  (v/v) with DOW and store in an amber 
bottle at 4 °C. 
6. Alkaline copper reagent. 
Add 0.5 ml of2% NAKC4H406.4H20 and 1% CuS04 .5H20 solutions to 50 ml of2% 
N�C03 in 0. 1 N sodium hydroxide solution (enough for 25 samples). Mix solutions 
thoroughly to avoid precipitation of Cu(OH) 2 . Prepare enough just prior to assay 
daily. 
7. 100/o and 0.5 mg/ml bovine serum albumin (BSA). 
Dissolve I Og of crystalline BSA in I 00 ml of saline. A working satndard is made by 
diluting the 100/o BSA with DDW to give 0.5 mg/ml BSA exactly. Store at less than 
0 °c. 
Procedure 
1 .  Set the protein standards and sample tubes as shown below: 
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Tube 0.5 mg/ml BSA DDW Alk. c11iso .. Folin Reagent µg PRO 
Blank (2 tubes) 0 µl 800 ul 2 ml 0.2 ml 0 
S I  1 5  785 2 0.2 7 
S2 30 770 2 0.2 1 5  
S3 60 740 2 0.2 30 
S4 90 710 2 0.2 45 
S5 120 680 2 0.2 60 
S6 1 50 650 2 0.2 75 
Sample 20-50 750-780 2 0.2 ? 
2. Add BSA standards or sample and DDW. Mix. 
3 .  Add 2.0 ml alkaline Cu2S04 solution. Mix. Stand at room temperature for 1 5  min. 
4. Add 0.2 ml diluted Folin reagent. Mix immediately and thoroughly. 
5 .  Stand for 30 min at room temperature. 
6. Read absorbance at 750 nm against blank. 
7 .  Plot the regression curve,, and get the linear regression equation. 
1 
0.9 
0.8 
E 
0.7 
C: 
0 0.6 
or 
0.5 
� 
0.4 
� 
0.3 
0.2 
0. 1 
0 
Calculation: 
0 1 0  
y = 0.01 5x + 1 E-05 
R2 = 0.998 
20 30 
BSA, mg 
40 
Protein Standard Curve 
µg Protein = Absorbance/Slope x Dilution Factor. 
1 2 1  
50 60 
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APPEND1X 6 
Glutathione S-Transferase Assay of Rat Hepatocytes 
Principle 
Glutathione S-Transferase (GST) catalyzes the conjugation of glutathione (GSH) with l­
chloro-2,4, dinitrobenzene (CDNB) which can be monitored spectrophotometrically at 
340 run. (Caution: CDNB is very toxic. Avoid skin contact and inhalation. Prepare 
under the hood). 
Reagents 
1 .  O. l M  sodium-phosphate buffer, pH 6.5 containing 1 mM EDTA 
2.84g NaJIP04 + 0.0584g EDTA in 1 80 ml DDW. Adjust pH to 6.5 .  Make-up to 
200 ml with DOW. Store at -4 °C. 
2. 20 mM GSH in DOW. 
0.061 5g GSH dissolve in IO ml DOW. Store at -20 °C. Stable for about 1 week. 
3 .  20 mM CDNB in 95% ethanol. 
0.0405g CDNB dissolve in 10 ml of 95% EtOH. Store at 4 °C. 
4. Hank's buffer. 
( or any other buffer that was used to suspend the cells) 
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Method 
Cytosol preparation from hepatocyte incubation mixture 
1 .  Prepare supernatant (SN) fraction from the incubation mixture immediately at the end 
of incubation, or after thawing the hepatocytes at -80 °C. All subsequent steps are 
done at 4 °C. 
2. Centrifuge 0.5 ml of incubation mixture (about 2 x 106 cells/ml) at 500 x g for IO min. 
Remove supernatant. 
3 .  Wash and suspend pellet with 0.5 ml Hank's Buffer (HB). Centrifuge and remove 
supernatant. 
4. Resuspend cells with 0.3 ml HB. Homogenize cell with a pellet pestle for 20 -30 sec. 
3 .  Transfer homogenized cells into a thick-wall Nalgene® ultratube ( 13  x 5 1  mm). 
4. Centrifuge homogenate at 9,000 x g for 15  min in a swinging bucket. 
5. Transfer SN to a new ultratube, and centrifuge at 100,000 x g for 60 min. 
6. Collect the SN ( cytosol) and determine protein content by Lowry method 
(APPENDIX) using BSA as standard. 
(Cytosol could be stored at -80 °C, but it must be centrifuged at 14000 rpm for 20 
min after thawing) 
Assay 
Control Sample 
O. IM sodium-phosphate buffer 8 50-89 5 µl 8 50-89 5 µl 
20 mM GSH in DDW 50 µl I 50 µI 
20 mM CDNB 50 µI 50 µl 
Hank's Buffer 5- 50 µI --
(Mix) 
Cell cytoso1 -- 5- 50 µI 
Total I ml I ml 
1 .  Prewarm the reagents and cytosol at 30 °C for 5- 10  min. or keep them at room 
temperature ( 2 5  °C) 
2. To two I-ml quartz cuvettte add the buffer, GSH, and CDNB, and for the Control 
cuvette add Hank's buffer. 
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3 .  Cap the cuvette with parafilm and mix the reaction mixture by inverting the cuvette 2-3 
times. 
4. Measure spontaneous reaction by monitoring the rate of absorbance (A) at 3 40 nm 
(UV) for 3 min at 30 °C in a  Hitachi U- 2000 spectophometer with UV and visible light 
on. 
5. Cap the cuvette with parafilm and mix the reaction mixture by inverting the cuvette 2-3 
times. 
6. Monitor and plot the increased in A rate for 3 min. 
Calculation 
Specific activity 
(µmoVmg protein/min) 
= flA * V 
E * :MP 
= AA * 1 
9. 6 * :MP 
1 25 
fl.A = Rate of A change with enzyme - Rate of A change without enzyme (per min at 
3 40 run) 
V = Volume of reaction mixture = 1 ml 
E = Extinction coefficient ofCDNB = 9. 6 mM-1 cm-1 
:MP = mg of cytosolic protein 
Definition: 
Specific activity of GST is defined as the amount of the enzyme catalyzes the formation of 
one unit or 1 µmol of 2, 4-dinitrophenylglutathione per min at 30 °C using 1 mM ofGSH 
and CDNB per mg of protein. 
Reference: 
Habig et al. (1974) J Biol Chem 2 49 :7130-713 9 as described by Warholm et al. (1985) 
Methods in Enzymology 113 : 499-507. 
APPENDIX 7 
Total Glutathione Assay in Hepatocytes 
Principal 
I) 2GSH + DTNB - GSSG + 2TNB 
2) GSSG + NADPH + H+ -* 2GSH + NADP+ 
*GSSH Reductase 
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GSH is oxidised non-enzymatically with DTNB to produce GSSG and 2TNB. GSSG is 
then reduced to GSH enzymatically by GSSH reductase and NADPH. Total GSH is 
calculated by the rate of color change of DTNB at 4 12 run for 3-6* min minus the rate of 
reduction ofDTNB in absence ofGSH or GSSH (blank). The rate ofTNB formation is 
proportional to the total amount of GSH and GSSH. The rates are also monitored in 
known amount of GSH solutions (standards) to plot the caliberation curve. · 
(*3 min monitoring of the rate of change is sufficient to get the linear portion of the 
curve.) 
Reagents ( for about 100 assays) 
1. 100 ml of 10 mM HCI. 
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2. 10 ml of 10 % 5-sulfosalicyclic acid. 
3. 143 mM sodium phosphate and 6.3 mM EDTA (stock buffer). 
Mix 5.077g Na2HPO and 0.59 g EDT A-N3.i.2H20, flask and make-up to 250 ml with 
DOW; final pH 7.5. Keep at room temperature or at 4 °C. 
4. 0.3 mM NADPH buffer 
26.6 mg NADPH tetrasodium salt in 100 ml of stock buffer. Prepare daily and keep at 
4 °C. 
5. 266 U/ml GSSH reductase Type III (Bakers yeast). 
Dilute yeast enzyme to get 266 U/ml with stock buffer. Keep at 4 °C; stable for 2 
weeks. 
6. 6 mM 5,5'-dithiobis-(2-nitrobenzoic acid)(DTNB) in stock buffer. 
23.8 mg DTNB in IO  ml stock buffer. Store at 4 °C; stable for 2 weeks. 
7. 20 mM GSH Standard solution (stock standard solution). 
Dissolve 61.4 mg GSH in 10 ml DOW. Store frozen; stable for 1 weeks. 
Dilute stock standard solution with 5-sulfosalicylic acid to give 0.5, 1, 2, 3, and 4 nmol 
of GSH. Prepare daily. 
Hepatocyte or Blood Sample Preparations 
1. Hepatocyte or whole blood sample (20 µl) is added to 100 µl of 1 O mM HCL in a 400 
µl or 1. 5 ml microcentrifuge tube. 
2. Lyse cell by freezing in liquid nitrogen or dry-ice acetone bath, and thaw. 
3. Repeat Step 2 for 3 more times. 
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4. Centrifuge in a Beckman microfuge at 10,000 g for 5 min. 
5. Transfer 100 µI of the supernatant into a new microcentrifuge tube. 
6. Add 50 µI of 10% 5-sulfosalicylic acid and mix to deproteinized the supernatant. 
7. Centrifuge in a Beckman microfuge at 10,000 g for 5 min. 
8. Up to 25 µI of the protein-free supernatant can be used for assay. 
Assay 
Reference/Blank Standard/Sample 
NADPH buffer 
I 
700 µI 700 µI 
I DTNB 100 µI 100 µI 
DOW 200 µI 175 µI 
(Cap with para.film, mix, and 
warm at 30 °Cfor 5 min) 
Protein-free sample -- 25 µI 
(Cap, mix, and zero the Abs) 
GSSG reductase 5-10 µI 5-10 µI 
Cap, mix, zero Abs., and read 
change in absorbance at 412 
run for 3 min. 
1. Add the NADPH, DBNB, and DOW into two 1.5 microcentrifuge tubes. 
2. Vortex and incubate at 3 7 ° C for 3 min. 
3.  Add 25 µl sample ( or blank and standards) to sample cuvet, and mix. 
4. Add GSSH reductase to both reference and sample cuvets, and mix gently. 
5. Transfer the reaction mixtures into 1.0 ml quartz cuvets. 
6. Zero absorbance, and start monitoring change in absorbances for 3 min. 
7. Run the assay for GSH standards containing 0, 0.5,  1 ,  2, 3, and 4 nmol of GSH 
equivalent. 
8. Plot rate of absorbance change against GSH equivalent. 
9. The amount of total glutathione in sample is calculated from the regression equation 
obtained from standard curve graph. 
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(For other samples, other extraction procedures are outlined by Griffith ( 1985) and 
Anderson ( 1985). Use the equations in Griffith (1985) to calculate for blood, plasma, and 
tissues gl utathione contents) 
References 
1 .  Griffith ( 1985) Methods in Enzymology VIII: 521 -529. 
2. Anderson ( 1985) Methods in Enzymology 1 1 3: 548-555.  
APPEND1X 8 
Isolation of Microsomes from Rat Liver 
Method 
1 .  Anesthetize rat with metofane in a jar. 
2. Perfuse rat with about 1 00 ml ice-cold physiological saline. 
3 .  Add 20 ml of0. 1 54 M KCl containing 0.0 1 M KH2P04 (pH 7.4) to 4 g liver (25% 
w/v), and homogenize(6 complete strokes) in a Teflon-glass homogenizer. 
4. Centrifuge homogenate at 10,000 x g for 10 min at 4 °C. 
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5.  Transfer supernatant (SN) into clean centrifuge tubes and centrifuge at 105,000 x g for 
60 min at 4 °C. 
6. Collect the SN (cytosol) into new tubes. 
7. Resuspend microsomal pellet in 4 ml ( 1 ml/g tissue) of glycerol-phosphate buffer ( 1 :  1 ,  
glycerol:0. 1 5M KH2P04, pH7.8). 
8. Determine protein content by the method ofLowry et al. (195 1) 
9. Store at -80 °C . 
Reference 
Kato, R. ( 1966) P450 and microsomal oxidation of drugs. J. Biochem. 59: 574-579. 
APPEND1X 9 
Binding of AFB1 to Exogenous DNA in a Microsomal System 
Method 
1 .  Triplicate samples are prepared as follows: 
CONTROL 
0.5 M Phosphate Buffer 200 µI 
.. 
lOO M NADPH 20 µl 
[3H]AFB 1 ,  2 nmoV20 ml 20 µ1 
DMSO 
Microsomes, 1 mg protein 200 µI 
equivalent 
4 mg/ml Calf Thymus DNA 25 µI 
10  mM L-CNE, pH 7.0 0 µI 
DDW 535 µl 
TOTAL 1000 µI 
2. Incubate the incubation mixtures at 37 °C for 30 min. 
1.2 mM L-CNE 
200 µI 
20 µI 
20 µ1 
200 µI 
50 µl 
120 µI 
4 1 5  µl 
1000 µI 
1 3 1  
I 
3. Add O .245 ml 5M NaCl to produce a mixture containing IM NaCl, 2 ml of 
chloroform:isoamyl alcohol (24: 1 ; v/v), and 0.9 mg calf thymus DNA (0.225 ml of 
4 mg/ml DNA) as carrier. 
4. Shake the tubes for 1 0  min, and centrifuge at 10,000 x g for 10 min. 
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5. Transfer an the top layer (DNA fraction) to new tubes, add 2 m1 ch1oroform:isoamy1 
alcohoi shake for 10  min., and centrifuge at 10,000 x g for 10 min. 
6. Transfer the top layer to new tubes. 
7. Add equal vol. of95% ethanol to precipitate DNA. Vortex. Centrifuge at 1 0,000 x g 
for 10  min. Remove SN. 
8. Dissolve DNA in 1 ml of O. lM NaCl (pH 7.0). 
9. Determine DNA content by Ceriotti ( 1 952) (APPENDIX 4). 
10. Transfer 200 ul ofDNA solution into scintillation vials, add 5 ml scintillation fluid, 
and DPM for 10 min. 
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